Bispecific antibodies against TL1A and IL23P19 and their applications

By designing bispecific antibodies that specifically bind to TL1A and IL23P19, and utilizing specific HCDR and LCDR sequences, the problem of insufficient specificity in antibody therapy in existing technologies has been solved. This approach achieves simultaneous blockade of TL1A and IL23P19, reduces inflammatory response and fibrosis, and improves therapeutic efficacy.

CN123106915APending Publication Date: 2026-11-17HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202610681735.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-06-09
Filing Date
2026-05-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies have difficulty effectively combining bispecific antibodies against TL1A and IL23P19, resulting in insufficient specificity and effectiveness of antibody therapy.

Method used

A bispecific antibody was designed, comprising an antigen-binding moiety that specifically binds to TL1A and IL23P19. By utilizing specific HCDR and LCDR sequences, it binds to the variable regions of the heavy and light chains to achieve simultaneous blocking of TL1A and IL23P19.

Benefits of technology

Simultaneous blocking of TL1A and IL23P19 was achieved, reducing the inflammatory response, alleviating intestinal inflammation, inhibiting the fibrosis process, and improving the specificity and efficacy of antibody therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106915A_ABST
    Figure CN123106915A_ABST
Patent Text Reader

Abstract

This invention relates to the field of biomedicine. Specifically, this invention provides bispecific antibodies against TL1A and IL23P19, pharmaceutical compositions comprising said bispecific antibodies, kits, and uses thereof. This invention further provides polynucleotides encoding said bispecific antibodies and expression vectors, as well as methods for generating said bispecific antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese Patent Application No. 202510629322.0, filed May 16, 2025, and Chinese Patent Application No. 202510759472.3, filed June 9, 2025, which are incorporated herein by reference in their entirety. Technical Field

[0002] This invention belongs to the field of biomedicine. Specifically, this invention relates to bispecific antibodies against TL1A and IL23P19 and their uses. Background Technology

[0003] Tumor necrosis factor-like ligand 1A (TL1A), also known as vascular endothelial growth inhibitory factor (VEGI)-251 and TNFSF15 (tumor necrosis factor superfamily 15), is a member of the ligand tumor necrosis factor superfamily (TNFSF) and was discovered by Migone et al. in 2002. TL1A is expressed in various immune cells (such as monocytes, macrophages, dendritic cells, and T cells) and non-immune cells (such as synovial fibroblasts and endothelial cells). TL1A can bind to the death receptor (DR3) and activate the TRADD pathway. This complex exerts pro-inflammatory effects by regulating downstream pathways such as TRAF2, RIP1, PI3K, MAPKs, and NF-κB, thereby regulating the secretion of cytokines and chemokines. TL1A also stimulates the TH1 and TH17 pathways, exacerbating the intestinal inflammatory response. In addition, TL1A can activate fibroblasts, promoting their proliferation and collagen synthesis, thus intensifying the fibrosis process. Therefore, TL1A is an important factor in regulating inflammation and fibrosis.

[0004] IL-23 (also known as IL23) is primarily produced by activated dendritic cells, macrophages, and monocytes. It is a member of the IL-12 heterodimer cytokine family and consists of two subunits: p19 (also known as the IL-23 p19 subunit) and p40 (also known as the IL-23 p40 subunit), with the p40 subunit being shared with IL-12. IL-23 coordinates the inflammatory cytokine cascade, involving increased levels of TNF-α, IL-6, IFNc, and IL-17 in the gut. Similar results have been observed in brain and joint inflammation models, indicating that IL-23 is an important mediator of inflammatory responses in tissues. Transforming growth factor β (TGFβ) and IL-6 induce Th17 cells to express IL-23R, making them responsive to IL-23. In the absence of IL-23, the accumulation of Th17 cells decreases, suggesting that IL-23 may maintain or stabilize the Th17 response. There is a need in this field for bispecific antibodies that combine TL1A and IL23P19 to achieve better and more specific antibody therapeutic effects. Summary of the Invention

[0005] The present invention provides at least the following schemes involving bispecific antibodies against TL1A and IL23P19.

[0006] In one aspect, the present invention provides a bispecific antibody comprising a first antigen-binding moiety binding to TL1A and a second antigen-binding moiety binding to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3. The sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are selected from: (1) HCDR1, comprising the amino acid sequence of SEQ ID NO: 1; HCDR2, comprising the amino acid sequence of SEQ ID NO: 2; HCDR3, comprising the amino acid sequence of SEQ ID NO: 3; LCDR1, comprising the amino acid sequence of SEQ ID NO: 4; LCDR2, comprising the amino acid sequence of SEQ ID NO: 5; and LCDR3, comprising the amino acid sequence of SEQ ID NO: 6; or (2) HCDR1, comprising the amino acid sequence of SEQ ID NO: 7; HCDR2, comprising the amino acid sequence of SEQ ID NO: 8; HCDR3, comprising the amino acid sequence of SEQ ID NO: 9; LCDR1, comprising the amino acid sequence of SEQ ID NO: 10; LCDR2, comprising the amino acid sequence of SEQ ID NO: 11; and LCDR3, comprising the amino acid sequence of SEQ ID NO: 12; or 3) HCDR1, comprising the amino acid sequence of SEQ ID NO: 7; HCDR2, comprising the amino acid sequence of SEQ ID NO: 8; HCDR3, comprising the amino acid sequence of SEQ ID NO: 9; LCDR1, comprising the amino acid sequence of SEQ ID NO: 97; LCDR2, comprising the amino acid sequence of SEQ ID NO: 11; and LCDR3, comprising the amino acid sequence of SEQ ID NO: 12; or (4) HCDR1, comprising the amino acid sequence of SEQ ID NO: 7; HCDR2, comprising the amino acid sequence of SEQ ID NO: 98; HCDR3, comprising the amino acid sequence of SEQ ID NO: 9; LCDR1, comprising the amino acid sequence of SEQ ID NO: 10; LCDR2, comprising the amino acid sequence of SEQ ID NO: 11; and LCDR3, comprising the amino acid sequence of SEQ ID NO: 12; or (5) HCDR1, which contains the amino acid sequence of SEQ ID NO: 7; HCDR2, which contains the amino acid sequence of SEQ ID NO: 98; HCDR3, which contains the amino acid sequence of SEQ ID NO: 9; LCDR1, which contains the amino acid sequence of SEQ ID NO: 97; LCDR2, which contains the amino acid sequence of SEQ ID NO: 11; and LCDR3, which contains the amino acid sequence of SEQ ID NO: 12.

[0007] In some embodiments, the heavy chain variable region and light chain variable region of the first antigen-binding portion of TL1A are selected from: (1) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14; or, (2) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16; or, (3) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 29; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30; (4) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 32; (5) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 31; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 30; (6) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 15; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 17; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18; a light chain variable region comprising the amino acid sequence of SEQ ID NO: 19 ... The amino acid sequence of SEQ ID NO: 82; the light chain variable region, which contains the amino acid sequence of SEQ ID NO: 83.

[0008] In some embodiments, the second antigen-binding moiety binding IL23P19 includes a heavy chain variable region and a light chain variable region; or, the second antigen-binding moiety binding IL23P19 includes a heavy chain variable region such as VHH.

[0009] In some embodiments, the second antigen-binding heavy chain variable region of the IL23P19 binding moiety includes HCDR1, HCDR2, and HCDR3.

[0010] In some embodiments, the heavy chain variable region of the second antigen-binding moiety binding IL23P19 comprises: (1) HCDR1, which comprises the amino acid sequence of SEQ ID NO: 17; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 18; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 19; or, (2) HCDR1, which comprises the amino acid sequence of SEQ ID NO: 20; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 21; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 22; or, (3) HCDR1, which comprises the amino acid sequence of SEQ ID NO: 25; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 26; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 27.

[0011] In some embodiments, the second antigen-binding heavy chain variable region of IL23P19 comprises: (1) the amino acid sequence of SEQ ID NO: 23, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 23; or, (2) the amino acid sequence of SEQ ID NO: 24, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 24; or, (3) the amino acid sequence of SEQ ID NO: 28, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 24; The amino acid sequence of 28 has an amino acid sequence identity of at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0012] In some embodiments, the second antigen-binding moiety binding IL23P19 includes a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and the light chain variable region comprising LCDR1, LCDR2, and LCDR3, wherein the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are selected from: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 25; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 26; HCDR3, which comprises the amino acid sequence of SEQ ID NO: 27; LCDR1, which comprises the amino acid sequence of SEQ ID NO: 79; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 80; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 81.

[0013] In some embodiments, the second antigen-binding region that binds to IL23P19 may include a heavy chain variable region and a light chain variable region, which may be: a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 28; and a light chain variable region containing the amino acid sequence of SEQ ID NO: 78.

[0014] In some embodiments, the bispecific antibody further comprises the heavy chain constant region CH1 of an immunoglobulin. In some embodiments, the bispecific antibody further comprises the heavy chain hinge region of an immunoglobulin. In some embodiments, the bispecific antibody further comprises the Fc fragment of an immunoglobulin. In some embodiments, the bispecific antibody further comprises the light chain constant region (CL) of an immunoglobulin. In some embodiments, the bispecific antibody further comprises a linker.

[0015] In another aspect, the present invention also provides a pharmaceutical composition comprising the bispecific antibody of the present invention and a pharmaceutically acceptable carrier.

[0016] In another aspect, the present invention also provides a kit comprising the bispecific antibody or pharmaceutical composition of the present invention.

[0017] In another aspect, the present invention also provides the use of the bispecific antibody of the present invention, the pharmaceutical composition of the present invention, or the kit of the present invention in the preparation of a medicament for treating immune diseases.

[0018] In another aspect, the present invention also provides a polynucleotide encoding the bispecific antibody of the present invention.

[0019] In another aspect, the present invention also provides an expression vector comprising the polynucleotides of the present invention.

[0020] In another aspect, the present invention also provides a host cell comprising the polynucleotide of the present invention or the expression vector of the present invention.

[0021] In another aspect, the present invention also provides a method for generating the bispecific antibody of the present invention, the method comprising: a) culturing the host cell of the present invention under suitable conditions to express the bispecific antibody of the present invention; and b) isolating the bispecific antibody from the host cell or its culture. Attached Figure Description

[0022] Figures 1A-1F A schematic diagram of the structure of the candidate bispecific antibody is shown. Figure 1A Schematic diagrams of the structures B37-5-Ab11, B37-6-Ab12, B37-6m-Ab13, B35-1-Ab14, B37-6-Ab15, B37-6m-Ab16, B35-1-Ab17, and B37-5-Ab22; Figure 1B Schematic diagrams of the structures B37-5-Ab23, B37-6m-Ab25, B37-5-Ab35, B37-5-Ab36, B37-6m-Ab37, and B37-6m-Ab38; Figure 1C Schematic diagrams of the structures of B37-5-Ab24 and B37-6m-Ab26; Figure 1D Schematic diagrams of the structures of B37-5-Ab27 and B37-6m-Ab29; Figure 1E Schematic diagrams of the structures of B37-5-Ab28 and B37-6m-Ab30; Figure 1F The diagram shows the structures of B37-5-Ab31, B37-5-Ab32, B37-6m-Ab33, and B37-6m-Ab34.

[0023] Figure 2A This demonstrates the ability of the bispecific antibody to block the TLIA-DCR3 pathway; Figure 2B This demonstrates the ability of bispecific antibodies to block the TLIA-DR3 pathway.

[0024] Figure 3 shows the competitive SPR detection results of the bispecific antibody. Figures 3A-3C The competitive SPR detection results for B37-6m-Ab16 are shown. Figure 3D , 3E The results of competitive SPR detection for B37-5-Ab23 are shown.

[0025] Figure 4 shows the results of bispecific antibody reporter gene blocking activity. Figure 4A The blocking activity of B37-6m-Ab25 and B37-6m-Ab16 on the TL1A terminus is shown. Figure 4B The activity of B37-6m-Ab25 and B37-6m-Ab16 in blocking the IL23 terminus is shown. Figure 4C The TL1A blocking activities of B37-5-Ab35, B37-5-Ab36, B37-6m-Ab37 and B37-6m-Ab38 are shown. Figure 4D The IL23 blocking activities of B37-5-Ab35, B37-5-Ab36, B37-6m-Ab37, and B37-6m-Ab38 are shown. Figure 4E The IL23 blocking activities of B37-5-Ab27, B37-5-Ab28, B37-6m-Ab29, B37-6m-Ab30, B37-5-Ab31, B37-5-Ab32, B37-6m-Ab33 and B37-6m-Ab34 are shown.

[0026] Figure 5 shows the blocking activity of the bispecific antibody against primary PBMA and mouse spleen cells. Figure 5A The inhibitory activity of B37-5-Ab11 and B37-6m-Ab13, as well as B37-6m-Ab16 and B37-5-Ab22 on TL1A-induced IFNγ secretion was demonstrated. Figure 5B The activity of B37-6m-Ab16 and B37-5-Ab22 in inhibiting IL23-induced IL17 production was demonstrated; Figure 5CThe activity of B37-6m-Ab16 and B37-6m-Ab25 in inhibiting TL1A-induced IFNγ secretion was demonstrated; Figure 5D The activity of B37-6m-Ab16 and B37-6m-Ab25 in inhibiting IL23-induced IL17 production was demonstrated. Figure 5E The activity of B37-6m-Ab25, B37-5-Ab35, and B37-6m-Ab37 in inhibiting IL23-induced IL17 production was demonstrated. Figure 5F The activity of B37-6m-Ab25, B37-5-Ab35, and B37-6m-Ab37 in inhibiting TL1A-induced IFNγ secretion was demonstrated.

[0027] Figure 6 shows the efficacy results of the bispecific antibody in a TNBS-induced enteritis model in B-hTL1A / hIL23A / hIL12B mice. Figure 6A The results of the DAI score for B37-6m-Ab25 in the pharmacodynamic model are shown. Figure 6B The results of weight change in the pharmacodynamic model are shown; Figure 6C The results show the changes in colon length in the pharmacodynamic model of B37-6m-Ab25; Figure 6D The results show the changes in colon weight in the pharmacodynamic model of B37-6m-Ab25; Figure 6E The results show the changes in colon density of B37-6m-Ab25 in the pharmacodynamic model. Detailed Implementation

[0028] definition In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the terms and laboratory procedures related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are all widely used terms and routine procedures in their respective fields. To better understand this invention, definitions and explanations of relevant terms are provided below.

[0029] As used herein, “at least one species” or “one or more species” can mean 1, 2, 3, 4, 5, 6, 7, 8 or more species.

[0030] As used herein, the expressions “comprising,” “including,” “containing,” and “having” are open-ended, meaning they include the listed elements, steps, or components but do not exclude other unlisted elements, steps, or components. The expression “composed of” excludes any unspecified elements, steps, or components. The expression “essentially composed of” means that the scope is limited to the specified elements, steps, or components, plus optional elements, steps, or components that do not significantly affect the essential and novel nature of the claimed subject matter. It should be understood that the expressions “essentially composed of” and “composed of” are encompassed within the meaning of the expression “comprising.”

[0031] As used herein, the connecting term “and / or” between multiple referred elements should be understood to include both individual and combined options. In other words, “and / or” includes both “and” and “or”. For example, A and / or B includes A, B, and A+B. A, B, and / or C includes A, B, C, and any combination thereof, such as A+B, A+C, B+C, and A+B+C. Further elements qualified by “and / or” are understood in a similar manner and include any one of them and any combination thereof.

[0032] Unless otherwise stated, any numerical value or range of numerical values, such as concentration or concentration range, shall in any case be understood to be modified by the term “about”. Thus, numerical values ​​typically include ±10% of the stated value. For example, a concentration of 1 mg / mL includes 0.9 mg / mL to 1.1 mg / mL. Similarly, a concentration range of 1% to 10% (w / v) includes 0.9% (w / v) to 11% (w / v). As used herein, the use of numerical ranges explicitly includes all possible subranges, all individual numerical values ​​within that range, including integers and fractions within that range, unless the context clearly indicates otherwise.

[0033] As used herein, the terms "first polypeptide (chain)" and similar terms such as "second polypeptide (chain)," "third polypeptide (chain)," "fourth polypeptide (chain)," etc., are used for distinguishing purposes only and are not intended to limit the order or connection of these polypeptide (chains). Individual polypeptide (chains) may be the same or different from each other. If necessary, two or more first polypeptide (chains) may be included, which may be the same or different. The aforementioned terms used in different schemes may be the same or different.

[0034] As used herein, the term "IL23P19 antibody" or "anti-IL23P19 antibody" refers to an antibody molecule that specifically binds to IL23P19 (the IL23 p19 subunit) and is capable of inhibiting IL23P19 activity. Anti-IL23P19 antibodies inhibit IL23P19 activity relative to the absence of IL23P19 antibodies, for example, by at least partially or completely blocking IL23P19, reducing, preventing, or delaying IL23P19 activation, or inactivating, desensitizing, or downregulating IL23P19 signal transduction, activity, or amount. In some embodiments, IL23P19 antibodies can inhibit IL23P19 activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more compared to a control.

[0035] As used herein, the term "TL1A antibody" or "anti-TL1A antibody" refers to an antibody molecule that specifically binds to TL1A and inhibits TL1A activity. Anti-TL1A antibodies inhibit TL1A activity relative to the absence of TL1A antibodies, for example, by at least partially or completely blocking TL1A stimulation, reducing, preventing, or delaying TL1A activation, or inactivating, desensitizing, or downregulating TL1A signal transduction, activity, or amount. In some embodiments, anti-TL1A antibodies can inhibit TL1A activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more compared to a control.

[0036] The term "amino acid" is intended to encompass all amino acid molecules, whether natural or synthetic, that include both amino and acid functional groups and that can be contained in polymers comprising amino acids. Exemplary amino acids include naturally occurring amino acids; analogs, derivatives, and congeners; amino acid analogs with variable side chains; and all stereoisomers of any of the foregoing. As used herein, the term "amino acid" includes D- or L-optical isomers and peptide-like compounds.

[0037] The terms “polypeptide chain,” “polypeptide,” “peptide,” and “protein” (if single-chain) used interchangeably herein refer to polymers of amino acids of any length. The polymer may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acid components. The term also covers polymers of modified amino acids, where the modification is, for example, disulfide bond formation, glycosylation, esterification, acetylation, phosphorylation, or any other operation, such as conjugation with a labeled component. Polypeptides may be isolated from natural sources, produced from eukaryotic or prokaryotic hosts via recombinant techniques, or may be products of synthetic methods.

[0038] As used herein, “antibody” refers to an immunoglobulin or a fragment thereof that specifically binds to an antigenic epitope through at least one antigen-binding site. Antibody encompasses antibody fragments. As used herein, the term “antibody” includes synthetic antibodies, recombinant antibodies, multispecific antibodies (e.g., bispecific antibodies), human antibodies, non-human antibodies, humanized antibodies, chimeric antibodies, intracellular antibodies, and antibody fragments such as, but not limited to, VHH, Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, disulfide-linked Fv (dsFv), Fd fragments, Fd' fragments, single-chain Fv (scFv), single-chain Fab (scFab), biantibodies, anti-idiotypic (anti-Id) antibodies, or antigen-binding fragments of any of the above antibodies. The antibodies described herein include members of any immunoglobulin type (e.g., IgG, IgM, IgD, IgE, IgA, and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass (e.g., IgG2a and IgG2b).

[0039] As used herein, an "antibody fragment" or "antigen-binding fragment" refers to any portion of a full-length antibody that is less than the full length but contains at least a portion of the antibody's variable region (e.g., one or more CDRs and / or one or more antibody-binding sites) that binds to an antigen, and thus retains binding specificity and at least a portion of the full-length antibody's specific binding capacity. Therefore, an antigen-binding fragment refers to an antibody fragment containing an antigen-binding portion that binds to the same antigen as the derived antibody fragment. Antibody fragments include antibody derivatives produced by enzymatic treatment of a full-length antibody, as well as synthetically produced derivatives, such as recombinant derivatives. Antibodies include antibody fragments. Examples of antibody fragments include, but are not limited to, VHH, Fab, Fab', F(ab')2, single-chain Fv (scFv), Fv, dsFv, biantibodies, Fd and Fd' fragments, and other fragments, including modified fragments (see, for example, Methods in Molecular Biology, Vol 207: Recombinant Antibodies for Cancer Therapy Methods and Protocols (2003); Chapter 1; p 3-25, Kipriyanov). The fragments may comprise multiple chains linked together, for example by disulfide bonds and / or by peptide linkers. Antibody fragments generally contain at least or about 50 amino acids, and typically at least or about 200 amino acids. Antigen-binding fragments include any antibody fragment that, when inserted into an antibody frame (e.g., by replacing the corresponding region), acquires an antibody that specifically binds to the antigen.

[0040] As used herein, the terms "VHH," "VHH chain," "nanobody," and "single-domain antibody" have the same meaning and are used interchangeably. A VHH is a small, stable, and highly efficient antigen-recognizing unit formed by a single heavy chain variable domain, consisting of only one chain from the C-terminus to the N-terminus: FR4-CDR3-FR3-CDR2-FR2-CDR1-FR1. VHH-specific binding to epitopes does not require recognition by other antigen-binding domains (unlike conventional tetrapeptide chain antibodies, where epitopes are recognized by the VL and VH structure pair). Nanobodies possess excellent biological properties, with a molecular weight of 12-15 kDa, one-tenth the size of a complete antibody. They exhibit excellent tissue penetration, high specificity, and good water solubility. Due to their unique structural properties, they combine the advantages of traditional antibodies and small molecule drugs, almost overcoming the shortcomings of traditional antibodies such as long development cycles, low stability, and stringent storage conditions. They are gradually becoming an emerging force in next-generation antibody therapy, showing broad application prospects in immunodiagnosis and treatment. VHH includes, but is not limited to, natural antibodies produced by camelids, or antibodies produced by camelids that have been humanized, or antibodies obtained through phage display technology or yeast display technology.

[0041] As used herein, a "bispecific antibody" refers to an antibody that specifically binds to two different antigens. The bispecific antibody of this invention comprises an antigen-binding moiety that specifically binds to two different antigens, TL1A and IL23P19.

[0042] "Fc fragment" or "Fc region" generally refers to a crystallizable fragment obtained by digestion of conventional antibodies or heavy chain antibodies with papain. Typically, the Fc fragment of IgG or heavy chain antibodies may contain a partial hinge region, CH2, and CH3. In this article, the Fc fragment may contain at least a partial hinge region (e.g., all or part of the hinge region), CH2, and CH3.

[0043] Light chains are classified as κ or λ (Kappa or Lambda). Each heavy chain class can bind to a κ or λ light chain. Typically, light and heavy chains are covalently linked, and when immunoglobulins are produced by hybridomas, B cells, or genetically engineered host cells, the "tail" portions of the two heavy chains are linked together via covalent disulfide bonds or non-covalent connections. In the heavy chain, amino acids extend from the N-terminus at the bifurcation end of the Y-configuration to the C-terminus at the base of each chain. The basic structure of some antibodies (e.g., IgG antibodies) comprises two heavy chain subunits and two light chain subunits covalently linked by disulfide bonds to form a "Y" structure.

[0044] Both light and heavy chains are divided into regions with structural and functional homology. The terms "constant region" and "variable region" are used from a functional perspective. In this regard, it should be understood that the variable region (VL) of the light chain or the variable region (VH) of the heavy chain determines antigen recognition and specificity. Conversely, the constant region (CL) of the light chain and the constant region (CH1, CH2, or CH3) of the heavy chain endow biological properties such as secretion, transplacental migration, Fc receptor binding, complement binding, etc. By convention, the numbering of constant region domains increases with distance from the antigen-binding site or the N-terminus of the antibody. The N-terminal portion is the variable region, and the C-terminal portion is the constant region; the CH3 and CL domains actually comprise the carboxyl termini of the heavy and light chains, respectively.

[0045] As described above, variable regions (i.e., “binding domains”) allow binding molecules to selectively recognize and specifically bind to epitopes on antigens. That is, for example, the VL and VH domains, or complementarity-determining region (CDR) subgroups of an antibody binding molecule, combine to form variable regions that define the three-dimensional antigen-binding site. More specifically, the antigen-binding site is defined by three CDRs on the VH chain and three CDRs on the VL chain. These six “complementarity-determining regions” or “CDRs” are discontinuous short sequences of amino acids that are specifically localized to form binding domains as the antibody adopts its three-dimensional conformation in an aqueous environment. The remaining amino acids in the binding domains are called “framework (FR)” regions, exhibiting smaller intermolecular differences. The binding domains formed by the localized CDRs define a surface complementary to the epitope on the immunoreactive antigen. This complementary surface facilitates non-covalent binding of the antibody to its complementary epitope. The amino acids constituting the CDRs and framework regions of any given heavy or light chain variable region can be identified by conventional methods (see “Sequences of Proteins of Immunological Interest”, Kabat, E. et al., U.S. Department of Health and Human Services, (1983); and Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987), which are incorporated herein by reference in their full text). In this paper, the CDRs (CDRL or LCDR) of the light chain variable region may be referred to as LCDR1, LCDR2, and LCDR3, and the CDRs (CDRH or HCDR) of the heavy chain variable region may be referred to as HCDR1, HCDR2, and HCDR3.

[0046] In this invention, the amino acid sequence of the CDR can be as shown in the Kabat definition rules (see, for example, Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242; the CDR mentioned in the claims of this invention is a sequence shown in the Kabat definition rules).However, it is well known to those skilled in the art that antibody CDRs can be defined in various ways, such as Chothia (see, for example, Chothia, C. et al., Nature, 342, 877-883 (1989); and Al-Lazikani, B. et al., J. Mol. Biol., 273, 927-948 (1997)) based on the antibody's three-dimensional structure and the topology of the CDR loop; Kabat (see, for example, Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242) based on antibody sequence variability; and AbM (Martin, ACR and J. Allen (2007) “Bioinformatics tools for antibody engineering,” in S. Dübel (ed.), Handbook of Therapeutic Antibodies. Weinheim: Wiley-VCH Verlag, pp. 95–118), Contact (MacCallum, RM et al., (1996) J. Mol. Biol. 262:732-745), IMGT (Lefranc, M.-P., 2011 (6), IMGT, the International ImMunoGeneTicsInformation System Cold Spring Harb Protoc. and Lefranc, M.-P. et al., Dev.Comp. Immunol., 27, 55-77 (2003)), and the North CDR definition based on affinity propagation clustering using a large number of crystal structures. Those skilled in the art will understand that, unless otherwise specified, the terms “CDR” and “complementarity-determining region” for a given antibody or its region (e.g., variable region) should be understood to encompass the complementarity-determining region defined as described above by the known schemes described in this invention.Although the scope of protection sought in the claims of this invention is based on the sequence defined by the AbM definition rules, amino acid sequences corresponding to other CDR definition rules should also fall within the scope of protection of this invention.

[0047] Therefore, when referring to antibodies defined by a specific CDR sequence as defined in this invention, the scope of said antibody also includes antibodies whose variable region sequence contains the specific CDR sequence, but whose claimed CDR boundaries differ from those defined in this invention due to the application of different schemes (e.g., different assignment system rules or combinations).

[0048] As used herein, the terms “frame region” and “architecture region” are used interchangeably. As used herein, the terms “frame region,” “architecture region,” or “FR” residues refer to the amino acid residues in the antibody variable region other than the CDR sequence as defined above.

[0049] The "Fv" fragment, consisting of a VH and a VL domain connected by non-covalent interactions, is generally considered the smallest antigen-binding fragment containing an antigen-binding site. However, single variable domain (single-domain antibody) also possesses antigen-binding capability. A "single-chain Fv (scFv)" can be obtained by linking VH and VL domains via peptide linkers. Introducing disulfide bonds into Fv or scFv yields either a "disulfide-stable Fv (dsFv)" or a "single-chain disulfide-stable Fv (scdsFv or dsscFv)," respectively.

[0050] As used herein, the Fab fragment is an antibody fragment obtained by digesting a full-length immunoglobulin with papain, or a fragment with the same structure synthesized, for example, through recombinant methods. It comprises a complete antibody light chain (VL-CL), a variable region of the antibody heavy chain, and a constant region of the heavy chain (VH-CH1, also known as Fd). Linking the CL and CH1 regions of “Fab” with peptide linkers yields a single-chain “Fab (scFab)”. “F(ab')2” is an antibody fragment resulting from digestion of an immunoglobulin with pepsin at pH 4.0–4.5, or a fragment with the same structure synthesized, for example, through recombinant methods. It essentially comprises two Fab fragments linked by disulfide bonds in their hinge regions. “Fab'” is half of F(ab')2 and can be obtained by reducing the disulfide bonds in the hinge region of F(ab')2.

[0051] As used in this article, the term "hinge region" refers to the heavy chain portion of the molecule that connects the CH1 and CH2 domains. This hinge region is flexible, thus allowing the two N-terminal antigen-binding regions to move independently.

[0052] As used in this article, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms. The amino acid cysteine ​​contains a thiol group that can form a disulfide bond or bridge a second thiol group.

[0053] As used herein, the term "percentage (%) sequence identity" or "sequence identity" has a generally accepted definition in the art, referring to the percentage of identical amino acid sequences between two polypeptide sequences as determined by sequence alignment (e.g., by manual inspection or a known algorithm). This can be determined using methods known to those skilled in the art, such as publicly available computer software like BLAST, BLAST-2, Clustal Omega, and FASTA software.

[0054] In this document, amino acid sequences “derived from” or “from” a reference amino acid sequence are partially or entirely identical or homologous to the reference amino acid sequence. For example, an amino acid sequence derived from the heavy chain constant region of human immunoglobulin may have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the wild-type sequence from which the heavy chain constant region of human immunoglobulin from which it is derived.

[0055] Non-critical regions of peptides (e.g., CDR regions of antibodies, non-critical amino acids in framework regions, amino acids in constant regions) can be modified, for example by substituting, adding, and / or deleting one or more amino acids, without altering the peptide's function. Suitable conserved amino acid substitutions in peptides or proteins are known to those skilled in the art and can generally be performed without changing the biological activity of the resulting molecule. Typically, those skilled in the art recognize that single amino acid substitutions in non-essential regions of a peptide do not substantially alter its biological activity.

[0056] "Affinity" or "binding affinity" measures the strength of the binding between an antibody and an antigen through non-covalent interactions. Affinity can be determined using conventional techniques known in the art, such as biomembrane interference techniques (e.g., using the Octet Fortebio detection system), radioimmunoassay, surface plasmon resonance assay, enzyme-linked immunosorbent assay (ELISA), or flow cytometry (FACS).

[0057] "Specific binding" generally refers to a binding molecule, such as an antibody or its fragments, variants, or derivatives, binding to an epitope through its antigen-binding domain, and this binding requires some complementarity between the antigen-binding domain and the epitope. By this definition, a binding molecule is said to "specifically bind" to an epitope when it binds to it significantly more readily than it would to a random, unrelated epitope.

[0058] As used in this article, the term "EC" 50 The "half-maximum concentration" (MCC) refers to the concentration of a drug, antibody, or toxicant that induces a 50% response between baseline and maximum after a specific exposure time.

[0059] As used herein, the term "T cell-dependent cytotoxicity" or "TDCC" refers to a form of cytotoxicity in which T cells specifically bind to target cells carrying antigens and subsequently kill the target cells. To determine the TDCC activity of a molecule of interest, in vitro and in vivo TDCC assays can be performed using methods known in the art, such as lactate dehydrogenase (LDH) release assays.

[0060] As used herein, the terms "polynucleotide" and "nucleic acid" are used interchangeably to refer to polymers of deoxyribonucleotides (DNA) or polymers of ribonucleotides (RNA). The terms "polynucleotide sequence," "nucleic acid sequence," and "nucleotide sequence" are used interchangeably to refer to the sequence of nucleotides in a polynucleotide. Those skilled in the art will understand that the DNA coding strand (sense strand) and its encoded RNA can be considered to have the same nucleotide sequence, with the deoxythymidine nucleotide in the DNA coding strand sequence corresponding to the uridine nucleotide in its encoded RNA sequence.

[0061] As used herein, isolated nucleic acid molecules are nucleic acid molecules isolated from other nucleic acid molecules present in natural sources of nucleic acid molecules. “Isolated” nucleic acid molecules, such as cDNA molecules, may be substantially free of other cellular material or culture medium when prepared by recombinant technology, or substantially free of chemical precursors or other chemical components when chemically synthesized. Exemplary isolated nucleic acid molecules provided herein include isolated nucleic acid molecules encoding provided antibody or antigen-binding fragments.

[0062] As used herein, the term “expression” includes the transcription and / or translation of nucleotide sequences. Therefore, expression can involve the production of transcripts and / or peptides.

[0063] As used herein, a "vector" is a medium used to introduce exogenous polynucleotides into host cells, whereby the exogenous polynucleotides are amplified or expressed when the vector is transformed into a suitable host cell. Vectors typically remain free, but can be designed to integrate genes or portions thereof into the chromosome of the genome. As used herein, the definition of a vector encompasses plasmids, linearized plasmids, viral vectors, granules, phage vectors, phage particles, artificial chromosomes (e.g., yeast artificial chromosomes and mammalian artificial chromosomes), etc. Viral vectors include, but are not limited to, retroviral vectors (including lentiviral vectors), adenovirus vectors, adeno-associated virus vectors, herpesvirus vectors, poxvirus vectors, and baculovirus vectors, etc.

[0064] As used herein, a “host cell” is a cell used to receive, maintain, replicate, and amplify a vector. Host cells can also be used to express the polypeptide encoded by the vector. When a host cell divides, the nucleic acids contained in the vector replicate, thereby amplifying the nucleic acids. Host cells can be eukaryotic or prokaryotic cells. Suitable host cells include, but are not limited to, CHO cells, various COS cells, HeLa cells, and HEK cells such as HEK 293 cells.

[0065] Terms such as “treatment,” “curing,” “with treatment,” “relief,” or “with relief” refer to therapeutic measures that cure, alleviate, or reduce the symptoms of an existing diagnosed pathological condition or disorder, and / or halt or slow the progression of an existing diagnosed pathological condition or disorder. Terms such as “prevention,” “defense,” “avoidance,” or “containment” refer to preventive or preventative measures that prevent the progression of an undiagnosed target pathological condition or disorder. Therefore, “subjects in need” may include subjects who already have the disease; subjects who are susceptible to the disease; and subjects who need to prevent the disease.

[0066] As used in this article, “therapeutic effect” refers to the effect resulting from treatment of an individual, which alters, usually improves or enhances the symptoms of a disease or condition, or cures a disease or condition.

[0067] The term "therapeutic effective amount" refers to the amount of antibody, polypeptide, polynucleotide, small organic molecule or other drug that is effective for the disease or condition in the "treated" subject or mammal.

[0068] As used in this article, the term "subject" refers to a mammal, such as a human.

[0069] The antibody numbers used in this article (such as B37-5-Ab11, B37-6-Ab12, B37-6m-Ab13, B35-1-Ab14, B37-6-Ab15, B37-6m-Ab16, B35-1-Ab17, B37-5-Ab22, B37-5-Ab23, B37-6m-Ab25, B37-5-Ab35, B37-5-A) The designations (b36, B37-6m-Ab37, B37-6m-Ab38, B37-5-Ab24, B37-6m-Ab26, B37-5-Ab27, B37-6m-Ab29, B37-5-Ab28, B37-6m-Ab30, B37-5-Ab31, B37-5-Ab32, B37-6m-Ab33, B37-6m-Ab34) are used solely for distinguishing or identifying antibodies or products and are not intended to represent a characteristic of the antibodies or products of this invention. Those skilled in the art will understand that other antibodies or products may also use such designations for distinguishing or identifying purposes, but these do not necessarily refer to the same or equivalent antibodies or products. Similarly, similar numbers or designations used in the examples are merely for illustrative purposes, and the antibodies or products of this invention are defined by the features described in the appended claims.

[0070] Bispecific antibodies against TL1A and IL23P19 In one aspect, the present invention provides a bispecific antibody comprising a first antigen-binding portion that binds to TL1A and a second antigen-binding portion that binds to IL23P19. Preferably, the binding is specific. In some embodiments, the bispecific antibody is capable of specifically binding to TL1A and / or IL23P19.

[0071] Methods for constructing bispecific antibodies using antibodies or antigen-binding fragments of interest are well known to those skilled in the art (see, for example, WO1993008829; Suresh MR, et al. Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol. 1986;121:210-28.; and Traunecker A, et al. Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J. 1991 Dec;10(12):3655-9). Bispecific antibodies can be generated and isolated using a variety of techniques known in the art. For example, a polynucleotide encoding a bispecific antibody can be obtained using recombinant DNA technology, optionally cloned into an expression vector, and then transformed into a host cell with the polynucleotide or expression vector. The transformed host cell can be cultured under suitable conditions to allow expression of the polynucleotide or expression vector, and finally the bispecific antibody can be isolated and purified from the host cell or culture medium. Alternatively, the individual parts of the bispecific antibody can be obtained separately, for example, the first antigen-binding part and the second antigen-binding part as described herein can be obtained separately, and then the individual parts can be optionally coupled through a linker by enzymatic or chemical coupling technology to obtain a bispecific antibody that specifically binds TL1A and IL23P19.

[0072] As used herein, “first antigen-binding part” and “second antigen-binding part” refer to amino acid sequences containing antigen-binding sites that can bind to antigen epitopes, and their definitions fall within the scope of the meaning of antibody or antigen-binding fragment.

[0073] The first antigen-binding moiety can be any form of antibody or antigen-binding fragment, including but not limited to VHH, Fv, scFv, dsFv, scdsFv, Fab, scFab, Fab', and F(ab')2. In some embodiments, the first antigen-binding moiety binding TL1A comprises VH and VL, which respectively comprise HCDR1, HCDR2, and HCDR3 and LCDR1, LCDR2, and LCDR3 of the first antigen-binding moiety binding TL1A as defined in this invention. In some embodiments, the first antigen-binding moiety binding TL1A comprises VH and VL, which respectively comprise VH and VL of the first antigen-binding moiety binding TL1A as defined in this invention.

[0074] In some embodiments, the first antigen-binding region binding to TL1A includes a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH includes HCDR1, HCDR2, and HCDR3 from any of the sequences in SEQ ID NO: 13, 15, 29, 31, or 82; and the VL includes LCDR1, LCDR2, and LCDR3 from SEQ ID NO: 14, 16, 30, 32, or 83. The CDRs may be CDRs as defined by Kabat, IMGT, AbM, or Chothia. In some embodiments, the sequences of the CDRs are shown in Tables 1.1 and 1.2.

[0075] In some embodiments, the VH comprises HCDR1, HCDR2 and HCDR3 from SEQ ID NO: 13; and the VL comprises LCDR1, LCDR2 and LCDR3 from SEQ ID NO: 14.

[0076] In some embodiments, the VH comprises HCDR1, HCDR2 and HCDR3 from SEQ ID NO: 15; and the VL comprises LCDR1, LCDR2 and LCDR3 from SEQ ID NO: 16.

[0077] In some embodiments, the VH comprises HCDR1, HCDR2 and HCDR3 from SEQ ID NO: 29; and the VL comprises LCDR1, LCDR2 and LCDR3 from SEQ ID NO: 30.

[0078] In some embodiments, the VH comprises HCDR1, HCDR2 and HCDR3 from SEQ ID NO: 31; and the VL comprises LCDR1, LCDR2 and LCDR3 from SEQ ID NO: 32.

[0079] In some embodiments, the VH comprises HCDR1, HCDR2 and HCDR3 from SEQ ID NO: 31; and the VL comprises LCDR1, LCDR2 and LCDR3 from SEQ ID NO: 30.

[0080] In some embodiments, the VH comprises HCDR1, HCDR2 and HCDR3 from SEQ ID NO: 82; and the VL comprises LCDR1, LCDR2 and LCDR3 from SEQ ID NO: 83. In some embodiments, the bispecific antibody comprises a first antigen-binding moiety that binds to TL1A and a second antigen-binding moiety that binds to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 7; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 8; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 9. The light chain variable region comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 10; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 11; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 12.

[0081] In some embodiments, the bispecific antibody comprises a first antigen-binding moiety that binds to TL1A and a second antigen-binding moiety that binds to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 1; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 2; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 3. The light chain variable region comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 4; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 5; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 6.

[0082] In some embodiments, the bispecific antibody comprises a first antigen-binding moiety that binds to TL1A and a second antigen-binding moiety that binds to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 7; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 8; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 9. The light chain variable region comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 10; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 11; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 12.

[0083] In some embodiments, the bispecific antibody comprises a first antigen-binding moiety that binds to TL1A and a second antigen-binding moiety that binds to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 7; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 98; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 9. The light chain variable region comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 10; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 11; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 12.

[0084] In some embodiments, the bispecific antibody comprises a first antigen-binding moiety that binds to TL1A and a second antigen-binding moiety that binds to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 7; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 8; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 9. The light chain variable region comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 97; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 11; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 12.

[0085] In some embodiments, the bispecific antibody comprises a first antigen-binding moiety that binds to TL1A and a second antigen-binding moiety that binds to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 7; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 98; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 9. The light chain variable region comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 97; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 11; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 12.

[0086] In some embodiments, the bispecific antibody comprises a first antigen-binding moiety that binds to TL1A and a second antigen-binding moiety that binds to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 1; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 2; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 3. The light chain variable region comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 4; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 5; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 6.

[0087] In some embodiments, the bispecific antibody comprises a first antigen-binding moiety that binds to TL1A and a second antigen-binding moiety that binds to IL23P19. The first antigen-binding moiety comprises a heavy chain variable region (VH) and a light chain variable region (VL). The heavy chain variable region comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 7; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 8; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 9. The light chain variable region comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 10; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 11; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 12.

[0088] In some embodiments, the heavy chain variable region of the first antigen-binding portion of TL1A comprises: (1) an amino acid sequence of SEQ ID NO: 13, 15, 29, 31 or 82; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 13, 15, 29, 31 or 82.

[0089] In some embodiments, the light chain variable region of the first antigen-binding portion of TL1A comprises: (1) an amino acid sequence of SEQ ID NO: 14, 16, 30, 32 or 83; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 14, 16, 30, 32 or 83.

[0090] In some embodiments, the heavy chain variable region of the first antigen-binding portion of TL1A contains the amino acid sequence of SEQ ID NO: 13, and the light chain variable region contains the amino acid sequence of SEQ ID NO: 14.

[0091] In some embodiments, the heavy chain variable region of the first antigen-binding moiety that binds to TL1A contains the amino acid sequence of SEQ ID NO:15, and the light chain variable region contains the amino acid sequence of SEQ ID NO:16.

[0092] In some embodiments, the heavy chain variable region of the first antigen-binding moiety that binds to TL1A contains the amino acid sequence of SEQ ID NO:29, and the light chain variable region contains the amino acid sequence of SEQ ID NO:30.

[0093] In some embodiments, the heavy chain variable region of the first antigen-binding moiety that binds to TL1A contains the amino acid sequence of SEQ ID NO:31, and the light chain variable region contains the amino acid sequence of SEQ ID NO:32.

[0094] In some embodiments, the heavy chain variable region of the first antigen-binding moiety that binds to TL1A contains the amino acid sequence of SEQ ID NO:31, and the light chain variable region contains the amino acid sequence of SEQ ID NO:30.

[0095] In some embodiments, the heavy chain variable region of the first antigen-binding moiety that binds to TL1A contains the amino acid sequence of SEQ ID NO: 82, and the light chain variable region contains the amino acid sequence of SEQ ID NO: 83.

[0096] The second antigen-binding part can be any form of antibody or antigen-binding fragment, including but not limited to VHH, Fv, scFv, dsFv, scdsFv, Fab, scFab, Fab', and F(ab')2.

[0097] In some implementations, the second antigen-binding portion includes a heavy chain variable region and a light chain variable region of an antibody that specifically binds to IL23P19.

[0098] In some implementations, the second antigen-binding portion includes a heavy chain variable region, such as VHH, that specifically binds to IL23P19.

[0099] The heavy chain variable region and light chain variable region or VHH that specifically bind to IL23P19 are described, for example, in WO2007076524A2 or WO2009068627A2, the contents of which are incorporated herein by reference in their entirety.

[0100] In some embodiments, the second antigen-binding moiety binding IL23P19 includes a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3 of the second antigen-binding moiety binding IL23P19 as defined in this invention.

[0101] In some embodiments, the heavy chain variable region (e.g., VHH) of the second antigen-binding moiety of IL23P19 comprises: HCDR1, which contains the amino acid sequence of SEQ ID NO: 17; HCDR2, which contains the amino acid sequence of SEQ ID NO: 18; and HCDR3, which contains the amino acid sequence of SEQ ID NO: 19.

[0102] In some embodiments, the heavy chain variable region (e.g., VHH) of the second antigen-binding moiety of IL23P19 comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 20; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 21; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 22.

[0103] In some embodiments, the heavy chain variable region of the second antigen-binding moiety of IL23P19 comprises: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 25; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 26; and HCDR3, which comprises the amino acid sequence of SEQ ID NO: 27.

[0104] In some embodiments, the light chain variable region of the second antigen-binding portion of IL23P19 comprises: LCDR1, which comprises the amino acid sequence of SEQ ID NO: 79; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 80; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 81.

[0105] In some embodiments, the heavy chain variable region (e.g., VHH) of the second antigen-binding portion of IL23P19 comprises: 1) the amino acid sequence of SEQ ID NO: 23; or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 23.

[0106] In some embodiments, the heavy chain variable region (e.g., VHH) of the second antigen-binding portion of IL23P19 comprises: 1) the amino acid sequence of SEQ ID NO: 24; or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 24.

[0107] In some embodiments, the second antigen-binding moiety binding IL23P19 includes a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and the light chain variable region comprising LCDR1, LCDR2, and LCDR3, wherein the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are selected from: HCDR1, which comprises the amino acid sequence of SEQ ID NO: 25; HCDR2, which comprises the amino acid sequence of SEQ ID NO: 26; HCDR3, which comprises the amino acid sequence of SEQ ID NO: 27; LCDR1, which comprises the amino acid sequence of SEQ ID NO: 79; LCDR2, which comprises the amino acid sequence of SEQ ID NO: 80; and LCDR3, which comprises the amino acid sequence of SEQ ID NO: 81.

[0108] In some embodiments, the heavy chain variable region binding to the second antigen-binding portion of IL23P19 comprises: 1) the amino acid sequence of SEQ ID NO: 28; or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 28.

[0109] In some embodiments, the light chain variable region binding to the second antigen-binding portion of IL23P19 comprises: 1) the amino acid sequence of SEQ ID NO: 78; or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 78.

[0110] In some embodiments, the second antigen-binding portion of IL23P19 comprises VH and VL, which respectively comprise the VH and VL of the second antigen-binding portion of IL23P19 as defined in this invention.

[0111] In some embodiments, the second antigen-binding region that binds to IL23P19 may include a heavy chain variable region and a light chain variable region, which may be: a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 28; and a light chain variable region containing the amino acid sequence of SEQ ID NO: 78.

[0112] In some embodiments, the second antigen-binding moiety binding to IL23P19 comprises at least one (e.g., 1, 2, 3, or 4, preferably 2 or 4) (identical or different) VHHs that specifically bind to IL23P19. In some embodiments, the second antigen-binding moiety binding to IL23P19 comprises 2 or 4 (identical or different) VHHs that specifically bind to IL23P19.

[0113] In some embodiments, the VHH comprises: HCDR1, which contains the amino acid sequence of SEQ ID NO: 17; HCDR2, which contains the amino acid sequence of SEQ ID NO: 18; and HCDR3, which contains the amino acid sequence of SEQ ID NO: 19.

[0114] In some embodiments, the VHH comprises: HCDR1, which contains the amino acid sequence of SEQ ID NO: 20; HCDR2, which contains the amino acid sequence of SEQ ID NO: 21; and HCDR3, which contains the amino acid sequence of SEQ ID NO: 22.

[0115] In some embodiments, the VHH comprises: 1) the amino acid sequence of SEQ ID NO: 23; or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 23.

[0116] In some embodiments, the VHH comprises: 1) the amino acid sequence of SEQ ID NO: 24; or 2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 24.

[0117] In some embodiments, the bispecific antibody of the present invention further comprises an immunoglobulin constant region. The immunoglobulin constant region can be the heavy chain constant region (CH) and light chain constant region (CL) of any species of immunoglobulin. The heavy chain constant region can be derived from the heavy chain constant region of any subtype (e.g., IgA, IgD, IgE, IgG, and IgM), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass (e.g., IgG2a and IgG2b) of immunoglobulin, or a combination thereof. For example, the heavy chain constant region of IgG1 may include: all or part of the hinge region -CH2-CH3 or CH1-hinge region -CH2-CH3. The light chain constant region can be derived from the λ (Lambda) light chain or κ (Kappa) light chain constant region. In a preferred embodiment, the heavy chain constant region is the heavy chain constant region of human IgG1.

[0118] In some implementations, the bispecific antibody also includes the CH1 region of the heavy chain of an immunoglobulin.

[0119] In a preferred embodiment, the heavy chain constant region CH1 is the heavy chain constant region CH1 of human IgG1.

[0120] In a preferred embodiment, the heavy chain constant region CH1 contains the amino acid sequence of SEQ ID NO: 37.

[0121] In some implementations, the bispecific antibody also includes the heavy chain hinge region of an immunoglobulin.

[0122] In a preferred embodiment, the heavy chain hinge region is the heavy chain hinge region of human IgG1.

[0123] In some implementations, the heavy chain hinge region contains the amino acid sequence (EPKSCDKTHTCPPCP) of SEQ ID NO: 39.

[0124] In some implementations, the heavy chain hinge region contains the amino acid sequence of SEQ ID NO: 40 (EPKSSDKTHTCPPCP).

[0125] In some implementations, the bispecific antibody also contains the Fc fragment of an immunoglobulin.

[0126] In a preferred embodiment, the Fc fragment is the Fc fragment of the human IgG1 heavy chain.

[0127] In some implementations, the Fc fragment contains the T366W mutation at position 366, according to the EU number.

[0128] In some implementations, the Fc fragment contains a T366S mutation at position 366, depending on the EU number.

[0129] In some implementations, the Fc fragment contains the L368A mutation at position 368, according to the EU number.

[0130] In some implementations, the Fc fragment contains the Y407V mutation at position 407, according to the EU number.

[0131] In some implementations, the Fc fragment contains the Y349C mutation at position 349, according to the EU number.

[0132] In some implementations, the Fc fragment contains the S354C mutation at position 354, according to the EU number.

[0133] In some implementations, according to the EU number, the Fc fragment contains the Y349C mutation at position 349 and the T366S mutation, L368A mutation, and Y407V mutation (hole mutation) at positions 366, 368, and 407, respectively.

[0134] In some implementations, according to the EU number, the Fc fragment contains the S354C mutation at position 354 and the T366W mutation (knob mutation) at position 366.

[0135] In some implementations, the Fc fragment (hole mutation) contains the amino acid sequence of SEQ ID NO: 41.

[0136] In some implementations, the Fc fragment (hole mutation) contains the amino acid sequence of SEQ ID NO: 42.

[0137] In some implementations, the Fc fragment (knob mutation) contains the amino acid sequence of SEQ ID NO: 43.

[0138] In some implementations, the Fc fragment (knob mutation) contains the amino acid sequence of SEQ ID NO: 44.

[0139] In some implementations, the Fc fragment contains the amino acid sequence of SEQ ID NO: 45.

[0140] In some implementations, the Fc fragment (hole mutation) contains the amino acid sequence of SEQ ID NO: 46.

[0141] In some implementations, the bispecific antibody also includes the light chain constant region (CL) of an immunoglobulin.

[0142] In some implementations, the light chain constant region is the human κ light chain constant region.

[0143] In some implementations, the light chain constant region contains the amino acid sequence of SEQ ID NO: 50.

[0144] The first antigen-binding portion and the second antigen-binding portion may optionally be connected via a linker. In some embodiments, the first antigen-binding portion and the second antigen-binding portion are not connected via a linker. In other embodiments, the first antigen-binding portion and the second antigen-binding portion are connected via a linker, such as a peptide linker or a chemical bond. Preferably, the first antigen-binding portion and the second antigen-binding portion are connected via a peptide linker. Exemplary peptide linkers may include, but are not limited to, polyglycine (G), polyalanine (A), polyserine (S), or combinations thereof, such as GGAS, GGGS, GGGSG, or (G4S). n , where n is an integer from 1 to 20. The heavy chain variable region and light chain variable region of the first antigen-binding portion or the second antigen-binding portion may also optionally be connected by a linker. In some embodiments, the heavy chain variable region and light chain variable region of the second antigen-binding portion are connected by a linker.

[0145] In some embodiments, the bispecific antibody comprises one or more adapters. In some embodiments, the adapter is a GS adapter. In some embodiments, the adapter comprises the amino acid sequence of SEQ ID NO: 47, 48, or 49.

[0146] In some embodiments, the bispecific antibody comprises a first polypeptide chain and a second polypeptide chain. In some embodiments, the bispecific antibody comprises two first polypeptide chains and two second polypeptide chains. In some embodiments, the two first polypeptide chains are identical. In some embodiments, the two second polypeptide chains are identical.

[0147] In some implementations, the bispecific antibody comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain.

[0148] In some embodiments, the first polypeptide chain includes, from the N-terminus to the C-terminus, a heavy chain variable region of a second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, a heavy chain variable region of a second antigen-binding moiety of IL23P19 as defined in this invention, a heavy chain hinge region of an immunoglobulin as defined in this invention, and an Fc fragment of an immunoglobulin as defined in this invention.

[0149] In some implementations, the first polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39 or 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 41 or 42.

[0150] In some embodiments, the first polypeptide chain comprises (1) the amino acid sequence of SEQ ID NO:51 or 56; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO:51 or 56.

[0151] In some embodiments, the first polypeptide chain, from the N-terminus to the C-terminus, includes a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, an Fc fragment of the immunoglobulin as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, and a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention; and the second polypeptide chain, from the N-terminus to the C-terminus, includes a light chain variable region of the first antigen-binding moiety of TL1A as defined in this invention and a light chain constant region of the immunoglobulin as defined in this invention.

[0152] In some implementations, the first polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 29, 31 and 82; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39 or 40; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (7) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; and (8) The heavy chain variable region of the second antigen-binding portion of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23.

[0153] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 60 or 62; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 60 or 62.

[0154] In some embodiments, the first polypeptide chain, from the N-terminus to the C-terminus, includes a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention.

[0155] In some implementations, the first polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (5) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 29, 31 and 82; (6) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (7) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39 or 40; and (8) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45.

[0156] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 61 or 63; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 61 or 63.

[0157] In some embodiments, the first polypeptide chain, from the N-terminus to the C-terminus, includes a heavy chain variable region of a first antigen-binding moiety for TL1A as defined in this invention, a heavy chain constant region CH1 of an immunoglobulin as defined in this invention, a heavy chain hinge region of an immunoglobulin as defined in this invention, an Fc fragment of an immunoglobulin as defined in this invention, a linker as defined in this invention, a heavy chain variable region of a second antigen-binding moiety for IL23P19 as defined in this invention, a linker as defined in this invention, and a heavy chain variable region of a second antigen-binding moiety for IL23P19 as defined in this invention.

[0158] In some implementations, the first polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 293, and 821; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39 or 40; (4) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 46; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (7) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; and (8) The heavy chain variable region of the second antigen-binding portion of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23.

[0159] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 64 or 66; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 64 or 66.

[0160] In some embodiments, the first polypeptide chain, from the N-terminus to the C-terminus, includes a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention.

[0161] In some implementations, the first polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (5) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 29, 31 and 82; (6) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (7) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39 or 40; and (8) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 46.

[0162] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 65 or 67; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 65 or 67.

[0163] In some embodiments, the first polypeptide chain includes, from the N-terminus to the C-terminus, a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention.

[0164] In some implementations, the first polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39 or 40; and (5) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0165] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 56; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 56 or 67.

[0166] In some embodiments, the first polypeptide chain, from the N-terminus to the C-terminus, includes a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, an Fc fragment of the immunoglobulin as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, and a light chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention; and the second polypeptide chain, from the N-terminus to the C-terminus, includes a light chain variable region of the first antigen-binding moiety of TL1A as defined in this invention and a light chain constant region of the immunoglobulin as defined in this invention.

[0167] In some implementations, the first polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 29, 31 and 82; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39 or 40; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 28; (7) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; and (8) The light chain variable region of the second antigen-binding portion of IL23P19, which contains the amino acid sequence of SEQ ID NO: 78.

[0168] In some embodiments, the first polypeptide chain, from the N-terminus to the C-terminus, includes a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, an Fc fragment of the immunoglobulin as defined in this invention, a linker as defined in this invention, a light chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, and a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention; and the second polypeptide chain, from the N-terminus to the C-terminus, includes a light chain variable region of the first antigen-binding moiety of TL1A as defined in this invention and a light chain constant region of the immunoglobulin as defined in this invention.

[0169] In some implementations, the first polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 29, 31 and 82; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39 or 40; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (6) The light chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 78; (7) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; and (8) The heavy chain variable region of the second antigen-binding portion of IL23P19, which contains the amino acid sequence of SEQ ID NO: 28.

[0170] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 74, 75, 76 or 77; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 74, 75, 76 or 77.

[0171] In some embodiments, the second polypeptide chain includes, from the N-terminus to the C-terminus, a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention.

[0172] In some implementations, the second polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 29, 31 and 82; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39 or 40; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 43 or 44.

[0173] In some embodiments, the second polypeptide chain comprises (1) an amino acid sequence of SEQ ID NO: 52, 53, 54, 57, 58 or 59; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 52, 53, 54, 57, 58 or 59.

[0174] In some embodiments, the second polypeptide chain includes, from the N-terminus to the C-terminus, a light chain variable region of the first antigen-binding moiety of TL1A as defined in this invention and a light chain constant region of the immunoglobulin as defined in this invention.

[0175] In some implementations, the second polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The light chain variable region of the first antigen-binding moiety of TL1A, comprising an amino acid sequence of one of SEQ ID NO: 14, 16, 30, and 32; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0176] In some embodiments, the second polypeptide chain comprises (1) the amino acid sequence of SEQ ID NO: 34; or, (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 34.

[0177] In some embodiments, the second polypeptide chain includes, from the N-terminus to the C-terminus, a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention.

[0178] In some implementations, the second polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 29, 31 and 82; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (3) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 13, 15, 29, 31 and 82; (4) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (5) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39 or 40; and (6) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0179] In some embodiments, the second polypeptide chain comprises (1) an amino acid sequence of SEQ ID NO: 68, 70, 72 or 73; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 68, 70, 72 or 73.

[0180] In some embodiments, the third polypeptide chain includes, from the N-terminus to the C-terminus, a light chain variable region of the first antigen-binding moiety of TL1A as defined in this invention and a light chain constant region of immunoglobulin as defined in this invention.

[0181] In some implementations, the third polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The light chain variable region of the first antigen-binding moiety of TL1A, comprising an amino acid sequence of one of SEQ ID NO: 14, 16, 30, 32, and 83; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0182] In some embodiments, the third polypeptide chain comprises (1) the amino acid sequence of SEQ ID NO: 34, 36 or 55; or (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 34, 36 or 55.

[0183] In some embodiments, the third polypeptide chain includes, from the N-terminus to the C-terminus, a light chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, a linker as defined in this invention, a light chain variable region of the first antigen-binding moiety of TL1A as defined in this invention, and a light chain constant region of the immunoglobulin as defined in this invention.

[0184] In some implementations, the third polypeptide chain comprises, from the N-terminus to the C-terminus: (1) The light chain variable region of the first antigen-binding portion of TL1A, which contains an amino acid sequence of one of SEQ ID NO: 14, 16, 30, 32 and 83; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47, 48 or 49; (3) The light chain variable region of the first antigen-binding moiety of TL1A, comprising an amino acid sequence of one of SEQ ID NO: 14, 16, 30, 32, and 83; and (4) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0185] In some embodiments, the third polypeptide chain comprises (1) the amino acid sequence of SEQ ID NO: 69 or 71; or, (2) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 69 or 71.

[0186] In some implementations, the bispecific antibody comprises a first polypeptide chain and a second polypeptide chain.

[0187] In some implementations, the bispecific antibody comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain.

[0188] In some embodiments, the bispecific antibody comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain; wherein, from the N-terminus to the C-terminus, the first polypeptide chain comprises a heavy chain variable region of the second antigen-binding moiety binding IL23P19 as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety binding IL23P19 as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention; the second polypeptide chain from the N-terminus to the C-terminus comprises a heavy chain variable region of the first antigen-binding moiety binding TL1A as defined in this invention, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention; the third polypeptide chain from the N-terminus to the C-terminus comprises a light chain variable region of the first antigen-binding moiety binding TL1A as defined in this invention and a light chain constant region of the immunoglobulin as defined in this invention.

[0189] In some embodiments, the bispecific antibody comprises a first polypeptide chain and a second polypeptide chain; wherein the first polypeptide chain comprises a heavy chain variable region of a first antigen-binding moiety binding TL1A as defined in this invention, a heavy chain constant region CH1 of an immunoglobulin as defined in this invention, a heavy chain hinge region of an immunoglobulin as defined in this invention, an Fc fragment of an immunoglobulin as defined in this invention, a linker as defined in this invention, a light chain variable region and / or a heavy chain variable region or VHH of a second antigen-binding moiety binding IL23P19 as defined in this invention; and wherein the second polypeptide chain comprises a light chain variable region of a first antigen-binding moiety binding TL1A as defined in this invention and a light chain constant region of an immunoglobulin as defined in this invention.

[0190] In some embodiments, the bispecific antibody comprises a first polypeptide chain and a second polypeptide chain; wherein, from the N-terminus to the C-terminus, the first polypeptide chain comprises, as defined in this invention, a heavy chain variable region of a first antigen-binding moiety binding TL1A, a heavy chain constant region CH1 of an immunoglobulin, a heavy chain hinge region of an immunoglobulin, an Fc fragment of an immunoglobulin, a linker, a heavy chain variable region of a second antigen-binding moiety binding IL23P19, a linker, and a heavy chain variable region of a second antigen-binding moiety binding IL23P19; and the second polypeptide chain comprises, from the N-terminus to the C-terminus, a light chain variable region of a first antigen-binding moiety binding TL1A and a light chain constant region of an immunoglobulin.

[0191] In some embodiments, the bispecific antibody comprises a first polypeptide chain and a second polypeptide chain; wherein, from the N-terminus to the C-terminus, the first polypeptide chain comprises, as defined in this invention, a heavy chain variable region of the second antigen-binding moiety binding IL23P19, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety binding IL23P19, a linker as defined in this invention, a heavy chain variable region of the first antigen-binding moiety binding TL1A, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention; the second polypeptide chain comprises, from the N-terminus to the C-terminus, a light chain variable region of the first antigen-binding moiety binding TL1A and a light chain constant region of the immunoglobulin as defined in this invention.

[0192] In some embodiments, the bispecific antibody comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain; wherein, from the N-terminus to the C-terminus, the first polypeptide chain comprises, as defined in this invention, a heavy chain variable region of a first antigen-binding moiety binding TL1A, a heavy chain constant region CH1 of an immunoglobulin, a heavy chain hinge region of an immunoglobulin, an Fc fragment of an immunoglobulin, a linker, a heavy chain variable region of a second antigen-binding moiety binding IL23P19, a linker, and a heavy chain variable region of a second antigen-binding moiety binding IL23P19; the second polypeptide chain comprises, from the N-terminus to the C-terminus, a heavy chain variable region of a first antigen-binding moiety binding TL1A, a heavy chain constant region CH1 of an immunoglobulin, a heavy chain hinge region of an immunoglobulin, and an Fc fragment of an immunoglobulin; the third polypeptide chain comprises, from the N-terminus to the C-terminus, a light chain variable region of a first antigen-binding moiety binding TL1A and a light chain constant region of an immunoglobulin.

[0193] In some embodiments, the bispecific antibody comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain; wherein, from the N-terminus to the C-terminus, the first polypeptide chain comprises, as defined in this invention, a heavy chain variable region of the second antigen-binding moiety binding IL23P19, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety binding IL23P19, a linker as defined in this invention, a heavy chain variable region of the first antigen-binding moiety binding TL1A, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention; the second polypeptide chain comprises, from the N-terminus to the C-terminus, a heavy chain variable region of the first antigen-binding moiety binding TL1A, a heavy chain constant region CH1 of the immunoglobulin as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention; the third polypeptide chain comprises, from the N-terminus to the C-terminus, a light chain variable region of the first antigen-binding moiety binding TL1A and a light chain constant region of the immunoglobulin as defined in this invention.

[0194] In some embodiments, the bispecific antibody comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain; wherein, the first polypeptide chain, from its N-terminus to its C-terminus, comprises a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a linker as defined in this invention, a heavy chain variable region of the second antigen-binding moiety of IL23P19 as defined in this invention, a heavy chain hinge region of the immunoglobulin as defined in this invention, and an Fc fragment of the immunoglobulin as defined in this invention; the second polypeptide chain, from its N-terminus to its C-terminus, comprises a heavy chain variable region of the first antigen-binding moiety of TL1A as defined in this invention. The variable region, the linker as defined in this invention, the heavy chain variable region of the first antigen-binding portion of TL1A as defined in this invention, the heavy chain constant region CH1 of the immunoglobulin as defined in this invention, the heavy chain hinge region of the immunoglobulin as defined in this invention, and the Fc fragment of the immunoglobulin as defined in this invention; the third polypeptide chain from the N-terminus to the C-terminus includes the light chain variable region of the first antigen-binding portion of TL1A as defined in this invention, the linker as defined in this invention, the light chain variable region of the first antigen-binding portion of TL1A as defined in this invention, and the light chain constant region of the immunoglobulin as defined in this invention.

[0195] In some embodiments, the bispecific antibody comprises a first polypeptide chain and a second polypeptide chain; wherein, from the N-terminus to the C-terminus, the first polypeptide chain comprises, as defined in this invention, a heavy chain variable region of a first antigen-binding moiety binding TL1A, a heavy chain constant region CH1 of an immunoglobulin, a heavy chain hinge region of an immunoglobulin, an Fc fragment of an immunoglobulin, a linker, a heavy chain variable region of a second antigen-binding moiety binding IL23P19, a linker, and a light chain variable region of a second antigen-binding moiety binding IL23P19; and the second polypeptide chain comprises, from the N-terminus to the C-terminus, a light chain variable region of a first antigen-binding moiety binding TL1A and a light chain constant region of an immunoglobulin.

[0196] In some embodiments, the bispecific antibody comprises a first polypeptide chain and a second polypeptide chain; wherein, from the N-terminus to the C-terminus, the first polypeptide chain comprises, as defined in this invention, a heavy chain variable region of a first antigen-binding moiety binding TL1A, a heavy chain constant region CH1 of an immunoglobulin, a heavy chain hinge region of an immunoglobulin, an Fc fragment of an immunoglobulin, a linker, a light chain variable region of a second antigen-binding moiety binding IL23P19, a linker, and a heavy chain variable region of a second antigen-binding moiety binding IL23P19; and the second polypeptide chain comprises, from the N-terminus to the C-terminus, a light chain variable region of a first antigen-binding moiety binding TL1A and a light chain constant region of an immunoglobulin. In some implementations, the bispecific antibodies include bispecific antibodies B37-5-Ab11, B37-6-Ab12, B37-6m-Ab13, B35-1-Ab14, B37-6-Ab15, B37-6m-Ab16, B35-1-Ab17, B37-5-Ab22, B37-5-Ab23, B37-6m-Ab25, B37-5-Ab35, and B... 37-5-Ab36, B37-6m-Ab37, B37-6m-Ab38, B37-5-Ab24, B37-6m-Ab26, B37-5-Ab27, B37-6m -Ab29, B37-5-Ab28, B37-6m-Ab30, B37-5-Ab31, B37-5-Ab32, B37-6m-Ab33, B37-6m-Ab34.

[0197] In some implementations, the bispecific antibody comprises the polypeptide chain shown in Table 3.

[0198] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 51, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 52, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0199] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 51, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 53, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 36.

[0200] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 51, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 53, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0201] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 51, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 54, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 55.

[0202] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 56, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 57, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 36.

[0203] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 56, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 57, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0204] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 56, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 58, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 55.

[0205] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 56, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 59, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0206] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 60, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34.

[0207] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 61, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34.

[0208] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 62, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34.

[0209] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 63, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34.

[0210] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 64, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 59, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0211] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 66, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 57, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0212] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 65, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 59, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0213] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 67, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 57, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0214] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 56, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 68, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 69.

[0215] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 56, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 70, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 71.

[0216] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 56, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 72, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 69.

[0217] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 56, the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 71, and the third polypeptide chain contains the amino acid sequence of SEQ ID NO: 73.

[0218] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 74, and the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0219] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 75, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34.

[0220] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO: 76, and the second polypeptide chain comprises the amino acid sequence of SEQ ID NO: 34.

[0221] In some embodiments, the first polypeptide chain contains the amino acid sequence of SEQ ID NO: 77, and the second polypeptide chain contains the amino acid sequence of SEQ ID NO: 34.

[0222] Bispecific antibody B37-5-Ab11 In one aspect, the present invention provides a bispecific antibody B37-5-Ab11 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0223] The first polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A connector comprising the amino acid sequence of SEQ ID: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 41.

[0224] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 51.

[0225] The second polypeptide chain, from its N-terminus to its C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 43.

[0226] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 52.

[0227] The third polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0228] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0229] Bispecific antibody B37-6-Ab12 In one aspect, the present invention provides a bispecific antibody B37-6-Ab12 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0230] The first polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A connector comprising the amino acid sequence of SEQ ID: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 41.

[0231] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 51.

[0232] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 43.

[0233] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 53.

[0234] The third polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 32; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0235] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 36.

[0236] Bispecific antibody B37-6m-Ab13 In one aspect, the present invention provides a bispecific antibody B37-6m-Ab13 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0237] The first polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A connector comprising the amino acid sequence of SEQ ID: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 41.

[0238] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 51.

[0239] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 43.

[0240] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 53.

[0241] The third polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0242] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0243] Bispecific antibody B35-1-Ab14 In one aspect, the present invention provides a bispecific antibody B35-1-Ab14 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0244] The first polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A connector comprising the amino acid sequence of SEQ ID: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 41.

[0245] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 51.

[0246] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 82; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 43.

[0247] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 54.

[0248] The third polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 83; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0249] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 55.

[0250] Bispecific antibody B37-6-Ab15 In one aspect, the present invention provides a bispecific antibody B37-6-Ab15 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0251] The first polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A connector comprising the amino acid sequence of SEQ ID: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0252] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 56.

[0253] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0254] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 57.

[0255] The third polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 32; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0256] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 36.

[0257] Bispecific antibody B37-6m-Ab16 In one aspect, the present invention provides a bispecific antibody B37-6m-Ab16 or an antigen-binding fragment thereof targeting TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0258] The first polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A connector comprising the amino acid sequence of SEQ ID: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0259] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 56.

[0260] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0261] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 57.

[0262] The third polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0263] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0264] Bispecific antibody B35-1-Ab17 In one aspect, the present invention provides a bispecific antibody B35-1-Ab17 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0265] The first polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A connector comprising the amino acid sequence of SEQ ID: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0266] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 56.

[0267] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 82; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0268] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 58.

[0269] The third polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 83; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0270] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 55.

[0271] Bispecific antibody B37-5-Ab22 In one aspect, the present invention provides a bispecific antibody B37-5-Ab22 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0272] The first polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:23; (2) A connector comprising the amino acid sequence of SEQ ID: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO:24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0273] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 56.

[0274] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0275] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 59.

[0276] The third polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0277] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0278] Bispecific antibody B37-5-Ab23 In another aspect, the present invention provides a bispecific antibody B37-5-Ab23 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain and a second polypeptide chain.

[0279] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (7) A linker comprising the amino acid sequence of SEQ ID NO: 48; and (8) The heavy chain variable region of the second antigen-binding moiety of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23. Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 60.

[0280] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0281] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0282] Bispecific antibody B37-6m-Ab25 In another aspect, the present invention provides a bispecific antibody B37-6m-Ab25 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain and a second polypeptide chain.

[0283] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (7) A linker comprising the amino acid sequence of SEQ ID NO: 48; and (8) The heavy chain variable region of the second antigen-binding moiety of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23. Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 62.

[0284] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0285] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0286] Bispecific antibody B37-5-Ab24 In another aspect, the present invention provides a bispecific antibody B37-5-Ab24 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain and a second polypeptide chain.

[0287] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) A linker comprising the amino acid sequence of SEQ ID NO: 47; (5) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (6) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (7) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (8) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45.

[0288] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 61.

[0289] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0290] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0291] Bispecific antibody B37-6m-Ab26 In another aspect, the present invention provides a bispecific antibody B37-6m-Ab26 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain and a second polypeptide chain.

[0292] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) A linker comprising the amino acid sequence of SEQ ID NO: 47; (5) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (6) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (7) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (8) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45.

[0293] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 63.

[0294] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0295] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0296] Bispecific antibody B37-5-Ab27 In one aspect, the present invention provides a bispecific antibody B37-5-Ab27 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0297] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39; (4) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 46; (5) A linker comprising the amino acid sequence of SEQ ID NO: 47; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (7) A linker comprising the amino acid sequence of SEQ ID NO: 48; and The heavy chain variable region of the second antigen-binding moiety of IL23P19 contains the amino acid sequence of SEQ ID NO: 23. Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 64.

[0298] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0299] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 59.

[0300] The third polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0301] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0302] Bispecific antibody B37-6m-Ab29 In one aspect, the present invention provides a bispecific antibody B37-6m-Ab29 or an antigen-binding fragment thereof targeting TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0303] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39; (4) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 46; (5) A linker comprising the amino acid sequence of SEQ ID NO: 47; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (7) A linker comprising the amino acid sequence of SEQ ID NO: 48; and (8) The heavy chain variable region of the second antigen-binding moiety of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23. Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 66.

[0304] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0305] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 57.

[0306] The third polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0307] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0308] Bispecific antibody B37-5-Ab28 In one aspect, the present invention provides a bispecific antibody B37-5-Ab28 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0309] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) A linker comprising the amino acid sequence of SEQ ID NO: 47; (5) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (6) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (7) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (8) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 46.

[0310] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 65.

[0311] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0312] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 59.

[0313] The third polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0314] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0315] Bispecific antibody B37-6m-Ab30 In one aspect, the present invention provides a bispecific antibody B37-6m-Ab30 or an antigen-binding fragment thereof targeting TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0316] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) A linker comprising the amino acid sequence of SEQ ID NO: 47; (5) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (6) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (7) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (8) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 46.

[0317] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 67.

[0318] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (4) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0319] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 57.

[0320] The third polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0321] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0322] Bispecific antibody B37-5-Ab31 In one aspect, the present invention provides a bispecific antibody B37-5-Ab31 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0323] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0324] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 56.

[0325] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains the amino acid sequence of SEQ ID NO:29; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47; (3) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (4) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (5) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (6) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0326] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 68.

[0327] The third polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The light chain variable region of the first antigen-binding portion of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47; (3) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0328] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 69.

[0329] Bispecific antibody B37-5-Ab32 In one aspect, the present invention provides a bispecific antibody B37-5-Ab32 or an antigen-binding fragment thereof targeting TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0330] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 56.

[0331] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding portion of TL1A, which contains the amino acid sequence of SEQ ID NO:29; (2) A linker comprising the amino acid sequence of SEQ ID NO: 84; (3) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (4) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (5) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (6) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0332] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 70.

[0333] The third polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The light chain variable region of the first antigen-binding portion of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; (2) A linker comprising the amino acid sequence of SEQ ID NO:85; (3) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0334] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 71.

[0335] Bispecific antibody B37-6m-Ab33 In one aspect, the present invention provides a bispecific antibody B37-6m-Ab33 or an antigen-binding fragment thereof targeting TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0336] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0337] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 56.

[0338] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO:31; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47; (3) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (4) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (5) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (6) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0339] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 72.

[0340] The third polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The light chain variable region of the first antigen-binding portion of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; (2) A linker comprising the amino acid sequence of SEQ ID NO: 47; (3) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0341] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 69.

[0342] Bispecific antibody B37-6m-Ab34 In one aspect, the present invention provides a bispecific antibody B37-6m-Ab34 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain, a second polypeptide chain and a third polypeptide chain.

[0343] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 23; (2) A linker comprising the amino acid sequence of SEQ ID NO: 48; (3) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 24; (4) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 40; and (5) An Fc fragment (hole mutation) of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 42.

[0344] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 56.

[0345] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO:31; (2) A linker comprising the amino acid sequence of SEQ ID NO: 84; (3) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (4) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (5) The heavy chain hinge region of an immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and (6) An Fc fragment of an immunoglobulin (knob mutation) containing the amino acid sequence of SEQ ID NO: 44.

[0346] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 73.

[0347] The third polypeptide chain, from the N-terminus to the C-terminus, includes: (1) The light chain variable region of the first antigen-binding portion of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; (2) A linker comprising the amino acid sequence of SEQ ID NO: 85; (3) The light chain variable region of the first antigen-binding moiety of TL1A, which contains the amino acid sequence of SEQ ID NO: 30; and The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0348] Specifically, the third polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 71.

[0349] Bispecific antibody B37-5-Ab35 In another aspect, the present invention provides a bispecific antibody B37-5-Ab35 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain and a second polypeptide chain.

[0350] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 28; (7) A linker comprising the amino acid sequence of SEQ ID NO: 47; and (8) The light chain variable region of the second antigen-binding portion of IL23P19, which contains the amino acid sequence of SEQ ID NO: 78.

[0351] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 74.

[0352] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0353] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0354] Bispecific antibody B37-5-Ab36 In another aspect, the present invention provides a bispecific antibody B37-5-Ab36 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain and a second polypeptide chain.

[0355] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 29; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47; (6) The light chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 78; (7) A linker comprising the amino acid sequence of SEQ ID NO: 47; and (8) The heavy chain variable region of the second antigen-binding portion of IL23P19, which contains the amino acid sequence of SEQ ID NO: 28.

[0356] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 74.

[0357] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0358] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0359] Bispecific antibody B37-6m-Ab37 In another aspect, the present invention provides a bispecific antibody B37-6m-Ab37 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain and a second polypeptide chain.

[0360] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47; (6) The heavy chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 28; (7) A linker comprising the amino acid sequence of SEQ ID NO: 47; and (8) The light chain variable region of the second antigen-binding portion of IL23P19, which contains the amino acid sequence of SEQ ID NO: 78.

[0361] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 76.

[0362] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0363] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0364] Bispecific antibody B37-6m-Ab38 In another aspect, the present invention provides a bispecific antibody B37-6m-Ab38 or an antigen-binding fragment thereof against TL1A and IL23P19, wherein the antibody comprises a first polypeptide chain and a second polypeptide chain.

[0365] The first polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The heavy chain variable region of the first antigen-binding region of TL1A, which contains the amino acid sequence of SEQ ID NO: 31; (2) The heavy chain constant region CH1 of the immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 37; (3) The heavy chain hinge region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 39; (4) An Fc fragment of an immunoglobulin containing the amino acid sequence of SEQ ID NO: 45; (5) A connector comprising the amino acid sequence of SEQ ID NO: 47; (6) The light chain variable region of the second antigen-binding region of IL23P19, which contains the amino acid sequence of SEQ ID NO: 78; (7) A linker comprising the amino acid sequence of SEQ ID NO: 47; and (8) The heavy chain variable region of the second antigen-binding portion of IL23P19, which contains the amino acid sequence of SEQ ID NO: 28.

[0366] Specifically, the first polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 76.

[0367] The second polypeptide chain, from the N-terminus to the C-terminus, comprises: (1) The light chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 30; and (2) The light chain constant region of an immunoglobulin, which contains the amino acid sequence of SEQ ID NO: 50.

[0368] Specifically, the second polypeptide chain contains the amino acid sequence shown in SEQ ID NO: 34.

[0369] In some embodiments, the bispecific antibody or its antigen-binding fragment of the present invention has at least one of the following characteristics: 1) It possesses affinity activities for TL1A and IL23P19 proteins; 2) It has affinity activity for TL1A-positive cells and IL23P19-positive cells; 3) It has the function of blocking the TL1A-DR3 signal path, while not affecting (blocking) the TL1A-DCR3 signal path; 4) It has a blocking effect on the IL23-IL23R signaling pathway; 5) It has an inhibitory effect on the secretion of IFN-γ by human PBMCs; 6) It has an inhibitory effect on the secretion of IL17 by mouse spleen cells; 7) It improves DAI score and weight loss in TNBS-induced CD model in a dose-dependent manner. The higher the dose, the earlier the onset of action and the stronger the effect.

[0370] Polynucleotides, vectors and host cells In another aspect, the present invention provides a polynucleotide comprising a polynucleotide sequence encoding the bispecific antibody of the present invention that binds TL1A and IL23P19.

[0371] The polynucleotides of the present invention can be obtained using methods known in the art. For example, the polynucleotides of the present invention can be isolated from phage display libraries, yeast display libraries, immunized animals, immortalized cells, or chemically synthesized. The polynucleotides of the present invention can be codon-optimized for the host cell used for expression.

[0372] In another aspect, the present invention also provides expression vectors comprising the polynucleotides of the present invention. The expression vectors may further comprise additional polynucleotide sequences, such as regulatory sequences and antibiotic resistance genes. The polynucleotides of the present invention may be present in one or more expression vectors. In some embodiments, the polynucleotides of the present invention are prepared as recombinant nucleic acids. Recombinant nucleic acids can be prepared using techniques well known in the art, such as chemical synthesis, DNA recombination techniques (e.g., polymerase chain reaction (PCR) techniques), etc.

[0373] The present invention also provides a host cell comprising the polynucleotide or expression vector of the present invention. The polynucleotide or expression vector of the present invention can be introduced into a suitable host cell using various methods known in the art. These methods include, but are not limited to, liposome transfection, electroporation, viral transduction, and calcium phosphate transfection.

[0374] In a preferred embodiment, the host cell is used to express the bispecific antibody of the present invention that binds TL1A and IL23P19. Examples of host cells include, but are not limited to, prokaryotic cells (e.g., bacteria, such as Escherichia coli) and eukaryotic cells (e.g., yeast, insect cells, mammalian cells). Suitable mammalian host cells for antibody expression include, but are not limited to, foreign human cervical cancer cells (HeLa cells), human embryonic kidney cells (HEK cells, such as HEK 293 cells), Chinese hamster ovary (CHO) cells, and other mammalian cells suitable for antibody expression.

[0375] The present invention also provides a method for generating the bispecific antibody of the present invention that binds TL1A and IL23P19, comprising the following steps: a) Culturing the host cells of the present invention under suitable conditions to express the bispecific antibodies of the present invention; and b) Isolate the bispecific antibodies of the present invention from host cells or their cultures.

[0376] Pharmaceutical Composition The present invention also provides a pharmaceutical composition comprising the bispecific antibody against TL1A and IL23P19 of the present invention, the polynucleotide of the present invention or the expression vector of the present invention, and a pharmaceutically acceptable vector. In some embodiments, the pharmaceutical composition comprises the bispecific antibodies B37-5-Ab11, B37-6-Ab12, B37-6m-Ab13, B35-1-Ab14, B37-6-Ab15, B37-6m-Ab16, B35-1-Ab17, B37-5-Ab22, B37-5-Ab23, B37-6m-Ab25, B37-5-Ab35, B37- The pharmaceutical composition comprises 5-Ab36, B37-6m-Ab37, B37-6m-Ab38, B37-5-Ab24, B37-6m-Ab26, B37-5-Ab27, B37-6m-Ab29, B37-5-Ab28, B37-6m-Ab30, B37-5-Ab31, B37-5-Ab32, B37-6m-Ab33, B37-6m-Ab34, or combinations thereof. Preferably, the pharmaceutical composition comprises bispecific antibodies B37-6m-Ab16, B37-5-Ab22, and B37-6m-Ab25.

[0377] The pharmaceutical compositions described herein can be in various dosage forms, including but not limited to solid, semi-solid, liquid, powder, or lyophilized forms. For compositions containing antibodies or antigen fragments thereof, preferred dosage forms are typically, for example, injection solutions and lyophilized powders.

[0378] The pharmaceutical compositions provided herein can be administered to a subject by any method known in the art, such as systemic or local administration. Routes of administration include, but are not limited to, parenteral (e.g., intravenous, intraperitoneal, intradermal, intramuscular, subcutaneous, or intracavitary), local, epidural, or mucosal (e.g., intranasal, oral, vaginal, rectal, sublingual, or local) administration. Preferably, the pharmaceutical compositions are suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., by injection or infusion). Administration methods may include, for example, injection or infusion.

[0379] Those skilled in the art will understand that the exact dosage will depend on various factors, such as the pharmacokinetic properties of the pharmaceutical composition, the duration of treatment, the excretion rate of a particular compound, the therapeutic purpose, the route of administration, and the condition of the subject, such as the patient's age, health status, weight, sex, diet, medical history, and other factors known in the medical field. As a general guideline, the dosage range of the bispecific antibody or pharmaceutical composition combining TL1A and IL23P19 of the present invention is about 0.0001-100 mg / kg. Administration may be by intravenous infusion.

[0380] The term "therapeutic effective dose" as used herein refers to a dose that reduces the severity of disease symptoms, increases the frequency and duration of asymptomatic periods, or prevents damage or disability caused by disease-related suffering. Therapeutic effective doses can vary depending on many different factors, including the route of administration, target site, patient's physiological state, whether the patient is human or another animal, other drugs administered, and whether the treatment is prophylactic or therapeutic. In some embodiments, the patient is human, but non-human mammals, including transgenic animals, may also be treated. Therapeutic doses can be titrated using conventional methods known to those skilled in the art to optimize safety and efficacy.

[0381] Reagent test kit The present invention also provides a kit comprising the bispecific antibody or pharmaceutical composition of the present invention against TL1A and IL23P19, and instructions for use. The kit may also comprise a suitable container. In some embodiments, the kit further comprises a device for administration. The kit generally includes a label indicating the intended use and / or method of use of the kit contents. The term “label” includes any written or recorded material provided on or with the kit or otherwise accompanied by the kit.

[0382] In some implementations, the kit includes bispecific antibodies binding to TL1A and IL23P19: B37-5-Ab11, B37-6-Ab12, B37-6m-Ab13, B37-1-Ab14, B37-6-Ab15, B37-6m-Ab16, B35-1-Ab17, B37-5-Ab22, B37-5-Ab23, B37-6m-Ab25, and B37-5-Ab26. 35. B37-5-Ab36, B37-6m-Ab37, B37-6m-Ab38, B37-5-Ab24, B37-6m-Ab26, B37-5-Ab27, B37-6m -Ab29, B37-5-Ab28, B37-6m-Ab30, B37-5-Ab31, B37-5-Ab32, B37-6m-Ab33, B37-6m-Ab34 or combinations thereof.

[0383] treat In another aspect, the present invention relates to the use of the bispecific antibody, pharmaceutical composition or kit of the present invention against TL1A and IL23P19 in the preparation of a medicament for treating a disease in a subject.

[0384] The present invention also relates to bispecific antibodies, pharmaceutical compositions or kits targeting TL1A and IL23P19 for the treatment of diseases.

[0385] The present invention also provides a method for treating a disease in a subject, the method comprising administering to the subject a therapeutically effective amount of the present invention’s bispecific antibody against TL1A and IL23P19, a pharmaceutical composition, or a reagent in a kit (e.g., the present invention’s bispecific antibody against TL1A and IL23P19 or pharmaceutical composition).

[0386] In some implementations, the disease described above is an immune disease, selected from autoimmune diseases, allergic diseases, or immune-mediated inflammatory diseases.

[0387] As used herein, "immune diseases" include, but are not limited to, lupus erythematosus, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, inflammatory bowel disease, interstitial cystitis, ankylosing spondylitis, idiopathic arthritis, vitiligo, hidradenitis suppurativa, uveitis, alopecia areata, erythema multiforme, hypersensitivity vasculitis, glomerulonephritis, endocrine dermatitis, allergic conjunctivitis, allergic rhinitis, autoimmune hepatitis-like diseases, immune encephalomyelitis, airway allergic lung inflammation, graft-versus-host disease, and lupus nephritis. ANCA-associated vasculitis, myositis, Sjögren's syndrome, bullous pemphigoid, neuromyelitis optica spectrum disorder, atopic dermatitis, herpetic dermatitis, fatty degeneration, non-alcoholic steatohepatitis, primary biliary cirrhosis, membranous nephropathy, multiple sclerosis, immune thrombocytopenic purpura, transplantation, myasthenia gravis, scleroderma, antiphospholipid syndrome, aplastic anemia, autoimmune hemolytic anemia, autoimmune hypoparathyroidism, autoimmune hypopituitarism, autoimmune myocarditis, autoimmune oophoritis. Autoimmune orchitis, Behçet's disease, chronic inflammatory demyelinating polyneuropathy, giant cell arteritis, Goodpassuia syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, immunoglobulin A (IgA) neurological disorders, IgG4-related diseases, Kawasaki disease, Lambert-Eton myasthenia gravis syndrome, chronic Lyme disease, erosive corneal ulcers, morphine scleroderma, myasthenia gravis, neuromuscular rigidity, strabismus-clonic syndrome, optic neuritis, polyarteritis, polyarthritis, polyglandular autoimmune syndrome, primary... Biliary cirrhosis, rheumatoid arthritis, Sjögren's syndrome, asthma, allergic rhinitis, urticaria, contact dermatitis, allergic diseases, airway or lung diseases (COPD, COAD, COLD), bronchitis, dyspnea, emphysema, pneumoconiosis, bronchial hyperresponsiveness, (endogenous or exogenous) asthma, acute lung injury, and acute respiratory distress syndrome; wherein, the immune diseases are preferably: lupus erythematosus, ulcerative colitis, rheumatoid arthritis, psoriasis, scleroderma, Crohn's disease, inflammatory bowel disease, and atopic dermatitis.

[0388] In some embodiments, the bispecific antibody or its antigen-binding fragment or pharmaceutical composition of the present invention can also be administered in combination with one or more other therapies, such as treatment modalities and / or other therapeutic agents, for the purposes described herein, such as for the prevention and / or treatment of the related diseases or conditions mentioned herein. Beneficial effects The bispecific antibody combining TL1A and IL23P19 of the present invention has at least one of the following beneficial effects: 1) It has affinity activity for both TL1A and IL23P19 proteins; 2) It has affinity activity for both TL1A-positive and IL23P19-positive cells; 3) It blocks the TL1A-DR3 signaling pathway without affecting (blocking) the TL1A-DCR3 signaling pathway; 4) It blocks the IL23-IL23R signaling pathway; 5) It blocks the secretion of IFN-γ by human PBMCs; 6) It blocks the secretion of IL17 by mouse spleen cells; 7) It improves the DAI score and weight loss in the TNBS-induced CD model in a dose-dependent manner, with higher doses resulting in earlier onset and stronger efficacy; 8) Combined with DLS particle size analysis, the polymer formed by the bispecific antibody of the present invention has a small particle size, resulting in a lower risk of ADA.

[0389] Example A further understanding of the invention can be obtained by referring to the specific embodiments given herein, which are for illustrative purposes only and are not intended to limit the scope of the invention in any way. Obviously, many modifications and variations can be made to the invention without departing from its spirit, and therefore, these modifications and variations are also within the scope of protection claimed in this application. All proportions used herein include percentages, and unless otherwise specified, are by weight.

[0390] Example 1: Raw material preparation 1.1 Preparation of control antibody Preparation of control antibodies: This application uses anti-TL1A antibody PRA023 (Merck), anti-TL1A antibody Afimkibart (i.e., RVT-3101, Pfizer), anti-IL23p19 antibody Guselkumab (Johnson & Johnson), and anti-IL23p19 antibody Risankizumab (AbbVie) as positive control antibodies. PRA023 was prepared using patent applications WO2019209995A2 and WO2021081365A1, Afimkibart using patent application WO2015073580A1, Guselkumab using patent application WO2007076524A2, and Risankizumab using patent application WO2013165791A1, respectively. The VH and VL values ​​for Guselkumab are SEQ ID NO: 28 and SEQ ID NO: 78, respectively; for Risankizumab, the VH and VL values ​​are SEQ ID NO: 86 and SEQ ID NO: 87, respectively; for PRA023, the VH and VL values ​​are SEQ ID NO: 88 and SEQ ID NO: 89, respectively; and for Afimkibart, the VH and VL values ​​are SEQ ID NO: 90 and SEQ ID NO: 91, respectively. Gene synthesis of the target fragment and antibody preparation were performed using conventional techniques in the art.

[0391] After being identified using conventional techniques in the field, the control antibodies were confirmed to bind to TL1A protein and have normal anti-TL1A activity; they were also confirmed to bind to IL23 protein and have normal anti-IL23 activity.

[0392] 1.2 Construction of overexpression cell lines Human and monkey TL1A sequences were obtained from the NCBI database, with sequence numbers NM_005118.4 (hTL1A natural trimer, SEQ ID NO:93) and NC_088389.1 (cyno-TL1A, SEQ ID NO:94), respectively. Different species TL1A sequences were cloned into the lentiviral overexpression vector pCDH-CMV.MCS-EF1.CopGFP.T2A.Puro (Miaoling Plasmid Platform / P0268) using PCR. The constructed overexpression plasmids and viral packaging plasmids (psPAX2 and pMD2.G) were then transfected into HEK293T cells (Zebra Biotech / BM-HEK-293T) using Lipofectamine 2000 at a specific ratio for viral packaging. The virus-containing supernatant was collected approximately 48 hours later. HEK293T cells were infected with the collected viral supernatant to construct HEK293T-human-TL1A and HEK293T-cyno-TL1A cell lines. All overexpression cell lines were cultured in DMEM + 10% FBS + 1% P / S + 5 μg / mL puromycin during expansion. The constructed overexpression cell lines were evaluated using PF-06480605. The results showed that the hTL1A / cyno-TL1A overexpression cell lines were successfully constructed and can be used for subsequent experiments.

[0393] IL23 sequences were obtained using commercially available IL23 and DR3 reporter gene cell lines from Acro, catalog numbers CHEK-ATF166 (IL23R) and SCJUR-STF178 (DR3), respectively.

[0394] Example 2: Preparation and humanization of anti-TL1A chimeric antibody 2.1 Preparation of murine antibodies The TL1A protein (TL1A His tag, TLA-H5243) used for immunization was purchased from Beijing Baipusai Biotechnology Co., Ltd. Balb / c mice (female, 6-8 weeks old; Lingchang Bio / LC-BALB / c) were immunized subcutaneously with Mn adjuvant. A total of 4 immunizations were performed (2 weeks apart). After the serum titer reached ≥100K, the final immunization was performed to prepare for fusion and library construction.

[0395] Spleens from immunized mice were harvested under aseptic conditions. The spleens were gently crushed, ground, and passed through a 40-mesh sieve. Cells were then separated and placed in sterile PBS. The cells were washed twice after centrifugation at 1500 rpm for 5 min, resuspended in a specific volume of electroporation buffer, and incubated for 5 min. Mouse myeloma cells were collected in PBS. Following the same procedure as for spleen cells, myeloma cells (SP20) were washed twice after centrifugation at 1500 rpm for 5 min, resuspended in a specific volume of electroporation buffer, and incubated for 5 min. Mouse spleen cells and myeloma cells were then thoroughly mixed at a ratio of 1.5:1. Electroporation was performed on the cells under pre-set conditions. After fusion, an appropriate amount of culture medium (DMEM + 10% FBS + 1% HT + 1% P / S) was added, and cells were transferred to 96-well flat-bottomed cells at a density of 2E4 cells / well. After approximately 7-10 days, once the cells had grown to a sufficient number, the hybridoma supernatant was identified according to a pre-set screening protocol to produce clones of TL1A-specific antibodies.

[0396] In the hybridoma screening process, the TL1A monoclonal antibody PRA-023 was used as a positive control. First, FACS and ELISA methods were mainly used to detect the binding of hybridoma supernatant to human TL1A in 96-well plates for preliminary screening, and hybridoma clones with high binding and human TL1A were selected. Second, the TL1A / DR3 blocking function of the selected clone supernatant was measured, and clones with high affinity and activity were transferred to 96-well plates for subcloning experiments. Finally, after the subclones grew, 3-6 monoclonal supernatants of each subclone were selected for retesting. Finally, the confirmed monoclonal clones were amplified and sequenced.

[0397] 2.2 Preparation and Identification of Chimeric Antibodies Based on the sequencing results, the hybridoma heavy and light chains were conjugated into hIgG1 and then onto the expression vector. The vectors were expressed and purified in 293F cells to obtain candidate 35F8 and 37G6 chimeric antibodies (named TL1A-35 and TL1A-37, respectively), which were then functionally evaluated. The CDR sequences of the anti-TL1A antibodies in this embodiment are shown in Table 1 below. Table 1.1 shows the CDR sequences determined using the Kabat definition method.

[0398] Table 1.1. Light and heavy chain CDR sequences of anti-TL1A antibodies

[0399] It should be understood that different CDR sequences may be obtained by using different CDR numbering / definition schemes, all of which fall within the scope of the antibody sequences involved in this invention.

[0400] Table 1.2 below provides examples of CDR sequences obtained under other CDR definition methods (IMGT, AbM, and Chothia).

[0401] Table 1.2. CDR Sequences for Other CDR Definition Methods

[0402] The heavy chain variable region sequences of the selected hybridoma clones TL1A-35 and TL1A-37 were routinely synthesized at Sangon Biotech (Shanghai) Co., Ltd., and cloned into the pTT5-hIgG1-FC01.CH vector (Shanghai Xiangyao Biotechnology) containing the amino acid sequence of the IgG1 heavy chain constant region (SEQ ID NO: 92) via homologous recombination to obtain chimeric antibody heavy chain expression vectors. The corresponding light chain variable region sequences were routinely synthesized at Sangon Biotech (Shanghai) Co., Ltd., and cloned into the pTT5-hKappa.CL vector (Shanghai Xiangyao Biotechnology) containing the amino acid sequence CL (SEQ ID NO: 50) of the antibody κ light chain constant region via homologous recombination. The obtained chimeric antibody light chain expression vectors were transformed into *E. coli* DH5α and cultured overnight at 37°C. Endotoxin-free plasmid extraction was performed using an endotoxin-free plasmid extraction kit (vazyme, DC204-01) to obtain endotoxin-free antibody plasmids for eukaryotic expression.

[0403] ExpiCHO-S cells were seeded into 250 mL cell culture flasks and cultured in 50 mL of culture medium. 25 μg of light and heavy chain expression plasmids were co-transfected with PEI.

[0404] Cell supernatant was collected on day 5 post-transfection culture, centrifuged, and filtered using a 0.22 μM filter. Antibody was purified using Protein A (Borglon) and then dialyzed to PBS pH 7.2 buffer. Antibody concentration and purity were determined by absorbance measurement using a Nanodrop (Allsheng, Nano-300) spectrophotometer, and purity was verified by sodium dodecyl sulfate gel electrophoresis and Coomassie staining.

[0405] Humanization of chimeric antibodies: The purpose of humanizing antibodies is to retain 90-100% of the original binding affinity and 70-100% of the specificity of the VH and VK regions of the chimeric antibody. Site-directed mutagenesis at single high-risk locations in VH and VK is used to further humanize the antibody, improving binding affinity and specificity. The humanized antibody modification of this invention involves combining the CDR region of a mouse antibody variable region with the relatively conserved framework region (FR) of a human variable region, followed by gene recombination to express the corresponding protein. The above-mentioned chimeric antibody is humanized according to the following steps: ① Determine the CDR sequence according to the Kabat extended CDR partitioning method; ② Find the closest homologous sequence for each V / J region of the heavy and light chains in the phylogenetic sequence database; ③ Screen for the most closely matched human lineages and the lowest possible amount of reversion mutations to the heavy and light chains; ④ Construct the CDR region of the chimeric antibody onto the human backbone region; ⑤ Use sequence and structural features to determine the amino acid positions in the backbone region that maintain CDR function; ⑥ Perform reverse mutations at sequence positions identified as important; ⑦ Optimize amino acids at risk sites.

[0406] The light chain variable region and heavy chain variable region of the obtained humanized antibody are detailed in Table 2 and the sequence listing below.

[0407] Table 2 Humanized antibody sequences

[0408] The obtained humanized antibodies were prepared and identified using the same method as chimeric antibodies.

[0409] Example 3: Design and construction of bispecific antibodies against TL1A and IL23P19 This embodiment describes the structure and construction of expression vectors for anti-TL1A and IL23P19 bispecific antibodies. Twenty-four anti-TL1A and IL23P19 bispecific antibodies were designed and constructed. The IL23P19 antigen-binding sequence was derived from the VH and VL sequences of WO2007076524A2 (SEQ ID NO: 106 and SEQ ID NO: 116 of WO2007076524A2, respectively), and the IL23P19 antigen-binding sequence was derived from the VH sequence of WO2009068627A2 (SEQ ID NO: 2578 and SEQ ID NO: 2584 of WO2009068627A2).

[0410] The TL1A antigen binding sequence is as described in Example 2.

[0411] Antibody conformation such as Figure 1A-1F As shown, the corresponding amino acid sequences are shown in Table 3. The specific antibody conformations are described below: Antibody B37-5-Ab11: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:23; a linker containing the amino acid sequence of SEQ ID:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, containing the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, containing the amino acid sequence of SEQ ID NO:41. The second polypeptide chain, from N-terminus to C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 29; a heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and an Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 43. The third polypeptide chain, from N-terminus to C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-5-Ab11 is as follows. Figure 1A As shown.

[0412] Antibody B37-6-Ab12: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:23; a linker containing the amino acid sequence of SEQ ID:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, containing the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, containing the amino acid sequence of SEQ ID NO:41. The second polypeptide chain, from its N-terminus to its C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 31; a heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and an Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 43. The third polypeptide chain, from its N-terminus to its C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 32; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-6-Ab12 is as follows. Figure 1A As shown.

[0413] Antibody B37-6m-Ab13: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:23; a linker containing the amino acid sequence of SEQ ID:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, containing the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, containing the amino acid sequence of SEQ ID NO:41. The second polypeptide chain, from its N-terminus to its C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 31; a heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and an Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 43. The third polypeptide chain, from its N-terminus to its C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-6m-Ab13 is as follows. Figure 1A As shown.

[0414] Antibody B35-1-Ab14: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:23; a linker containing the amino acid sequence of SEQ ID:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, containing the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, containing the amino acid sequence of SEQ ID NO:41. The second polypeptide chain, from its N-terminus to its C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 82; a heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and an Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 43. The third polypeptide chain, from its N-terminus to its C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 83; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B35-1-Ab14 is as follows. Figure 1A As shown.

[0415] Antibody B37-6-Ab15: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:23; a linker containing the amino acid sequence of SEQ ID:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, containing the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, containing the amino acid sequence of SEQ ID NO:42. The second polypeptide chain, from its N-terminus to its C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 31; a heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and an Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 44. The third polypeptide chain, from its N-terminus to its C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 32; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-6-Ab15 is as follows. Figure 1A As shown.

[0416] Antibody B37-6m-Ab16: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:23; a linker containing the amino acid sequence of SEQ ID:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, containing the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, containing the amino acid sequence of SEQ ID NO:42. The second polypeptide chain, from N-terminus to C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 31; the heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; the heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and the Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 44. The third polypeptide chain, from N-terminus to C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and the light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-6m-Ab16 is as follows. Figure 1A As shown.

[0417] Antibody B35-1-Ab17: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:23; a linker containing the amino acid sequence of SEQ ID:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, containing the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, containing the amino acid sequence of SEQ ID NO:42. The second polypeptide chain, from N-terminus to C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 82; a heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and an Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 44. The third polypeptide chain, from N-terminus to C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 83; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B35-1-Ab17 is as follows: Figure 1A As shown.

[0418] Antibody B37-5-Ab22: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:23; a linker containing the amino acid sequence of SEQ ID:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, containing the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, containing the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, containing the amino acid sequence of SEQ ID NO:42. The second polypeptide chain, from N-terminus to C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 29; the heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; the heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and the Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 44. The third polypeptide chain, from N-terminus to C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and the light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-5-Ab22 is as follows. Figure 1A As shown.

[0419] Antibody B37-5-Ab23: comprises two identical first polypeptide chains and two identical second polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 29; a heavy chain constant region CH1 of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; an Fc fragment of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 45; a linker comprising the amino acid sequence of SEQ ID NO: 47; a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 24; a linker comprising the amino acid sequence of SEQ ID NO: 48; and a light chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 23. The second polypeptide chain, from the N-terminus to the C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-5-Ab23 is as follows: Figure 1B As shown.

[0420] Antibody B37-6m-Ab25: Contains two identical first polypeptide chains and two identical second polypeptide chains. The heavy chain variable region of the first antigen-binding moiety of the first polypeptide chain that binds to TL1A is the amino acid at SEQ ID NO:31. The remaining sequence information is the same as that of B37-5-Ab23. The conformation of antibody B37-6m-Ab25 is as follows. Figure 1B As shown.

[0421] Antibody B37-5-Ab24: comprises two identical first polypeptide chains and two identical second polypeptide chains. The first polypeptide chain, from N-terminus to C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 23; a linker comprising the amino acid sequence of SEQ ID NO: 48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 24; a linker comprising the amino acid sequence of SEQ ID NO: 47; a heavy chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 29; a heavy chain constant region CH1 of immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and an Fc fragment of immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 45. The second polypeptide chain, from the N-terminus to the C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-5-Ab24 is as follows: Figure 1C As shown.

[0422] Antibody B37-6m-Ab26 comprises two identical first polypeptide chains and two identical second polypeptide chains. The heavy chain variable region of the first antigen-binding moiety in the first polypeptide chain, which binds to TL1A, is the amino acid at SEQ ID NO:31. The remaining sequence information is identical to that of B37-5-Ab24. The conformation of antibody B37-6m-Ab26 is as follows: Figure 1C As shown.

[0423] Antibody B37-5-Ab27 comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The first polypeptide chain, from its N-terminus to its C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 29; a heavy chain constant region CH1 of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; an Fc fragment (hole mutation) of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 46; a linker comprising the amino acid sequence of SEQ ID NO: 47; a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 24; a linker comprising the amino acid sequence of SEQ ID NO: 48; and a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 23. The second polypeptide chain, from N-terminus to C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 29; the heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; the heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and the Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 44. The third polypeptide chain, from N-terminus to C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and the light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-5-Ab27 is as follows. Figure 1D As shown.

[0424] Antibody B37-6m-Ab29 comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The heavy chain variable region of the first antigen-binding moiety binding TL1A in the first and second polypeptide chains is the amino acid of SEQ ID NO:31; the remaining sequence information is the same as that of B37-5-Ab27. The conformation of antibody B37-6m-Ab29 is as follows. Figure 1D As shown.

[0425] Antibody B37-5-Ab28: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 23; a linker comprising the amino acid sequence of SEQ ID NO: 48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 24; a linker comprising the amino acid sequence of SEQ ID NO: 47; a heavy chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 29; a heavy chain constant region CH1 of immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and an Fc fragment (hole mutation) of immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 46. The second polypeptide chain, from N-terminus to C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 29; the heavy chain constant region CH1 of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 37; the heavy chain hinge region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 39; and the Fc fragment (knob mutation) of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 44. The third polypeptide chain, from N-terminus to C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and the light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-5-Ab28 is as follows. Figure 1E As shown.

[0426] Antibody B37-6m-Ab30: Contains a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The heavy chain variable region of the first antigen-binding moiety of the first polypeptide chain and the second polypeptide chain that binds TL1A is the amino acid of SEQ ID NO:31; the remaining sequence information is the same as that of B37-5-Ab28. The conformation of antibody B37-6m-Ab30 is as follows. Figure 1E As shown.

[0427] Antibody B37-5-Ab31: comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO:23; a linker comprising the amino acid sequence of SEQ ID NO:48; a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO:24; a heavy chain hinge region of immunoglobulin, comprising the amino acid sequence of SEQ ID NO:40; and an Fc fragment (hole mutation) of immunoglobulin, comprising the amino acid sequence of SEQ ID NO:42. The second polypeptide chain, from the N-terminus to the C-terminus, comprises: a heavy chain variable region of the first antigen-binding portion of TL1A, comprising the amino acid sequence of SEQ ID NO: 29; a linker comprising the amino acid sequence of SEQ ID NO: 47; a heavy chain variable region of the first antigen-binding portion of TL1A, comprising the amino acid sequence of SEQ ID NO: 29; a heavy chain constant region CH1 of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; and an Fc fragment (knob mutation) of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 44. The third polypeptide chain, from the N-terminus to the C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; a linker containing the amino acid sequence of SEQ ID NO: 47; the light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-5-Ab31 is as follows: Figure 1F As shown.

[0428] Antibody B37-5-Ab32: Contains a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The linker in the second polypeptide chain is the amino acid sequence of SEQ ID NO:84, and the linker in the third polypeptide chain is the amino acid sequence of SEQ ID NO:85; the remaining sequence information is the same as that of B37-5-Ab31. The conformation of antibody B37-5-Ab32 is as follows. Figure 1F As shown.

[0429] Antibody B37-6m-Ab33: Contains a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The heavy chain variable region of the first antigen-binding moiety of the second polypeptide chain, which binds to TL1A, is the amino acid of SEQ ID NO: 31. The remaining sequence information is the same as that of B37-5-Ab31. The conformation of antibody B37-6m-Ab33 is as follows: Figure 1F As shown.

[0430] Antibody B37-6m-Ab34: Contains a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain. The linker in the second polypeptide chain is the amino acid sequence of SEQ ID NO:84, and the linker in the third polypeptide chain is the amino acid sequence of SEQ ID NO:85. The remaining sequence information is the same as that of B37-6m-Ab33. The conformation of antibody B37-6m-Ab34 is as follows. Figure 1F As shown.

[0431] Antibody B37-5-Ab35 comprises two identical first polypeptide chains and two identical second polypeptide chains. The first polypeptide chain, from its N-terminus to its C-terminus, comprises: a heavy chain variable region of the first antigen-binding moiety of TL1A, comprising the amino acid sequence of SEQ ID NO: 29; a heavy chain constant region CH1 of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 37; a heavy chain hinge region of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 39; an Fc fragment of the immunoglobulin, comprising the amino acid sequence of SEQ ID NO: 45; a linker comprising the amino acid sequence of SEQ ID NO: 47; a heavy chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 28; a linker comprising the amino acid sequence of SEQ ID NO: 47; and a light chain variable region of the second antigen-binding moiety of IL23P19, comprising the amino acid sequence of SEQ ID NO: 78. The second polypeptide chain, from the N-terminus to the C-terminus, comprises: a light chain variable region of the first antigen-binding moiety of TL1A, containing the amino acid sequence of SEQ ID NO: 30; and a light chain constant region of the immunoglobulin, containing the amino acid sequence of SEQ ID NO: 50. The conformation of antibody B37-5-Ab35 is as follows: Figure 1B As shown.

[0432] Antibody B37-5-Ab36 comprises two identical first polypeptide chains and two identical second polypeptide chains. The heavy chain variable region and light chain variable region of the second antigen-binding moiety in the first polypeptide chain are interchanged with those in B37-5-Ab35, while the remaining sequence information is identical to that of B37-5-Ab35. The conformation of antibody B37-5-Ab36 is as follows. Figure 1B As shown.

[0433] Antibody B37-6m-Ab37 comprises two identical first polypeptide chains and two identical second polypeptide chains. The variable region of the heavy chain in the first antigen-binding moiety of the first derivatized chain, which binds to TL1A, is the amino acid sequence SEQ ID NO:31. The remaining sequence information is identical to that of B37-5-Ab35. The conformation of antibody B37-6m-Ab37 is as follows: Figure 1B As shown.

[0434] Antibody B37-6m-Ab38 comprises two identical first polypeptide chains and two identical second polypeptide chains. The heavy chain variable region and light chain variable region of the second antigen-binding moiety in the first polypeptide chain interchange sequence positions with those in B37-6m-Ab37; the remaining sequence information is identical to that of B37-6m-Ab37. The conformation of antibody B37-6m-Ab38 is as follows: Figure 1B As shown.

[0435] Table 3. Amino acid sequences of 24 bispecific antibodies

[0436] Example 4: Expression, purification, and physicochemical property analysis of anti-TL1A and anti-IL23P19 bispecific antibodies. 4.1 Expression and purification of anti-TL1A and IL23P19 specific antibodies The antibody in Example 3 was expressed using the ExpiCHO transient transfection system (Thermo Fisher, A29133), and cell transfection was performed using conventional techniques in the art.

[0437] The CHO cell density was confirmed to be 7 × 10⁻⁶. 6 -1×10 7 With a cell density of approximately 6 × 10⁶ cells / mL and a cell viability >98%, the cells were then adjusted to a final concentration of 6 × 10⁶ cells / mL using fresh ExpiCHO expression medium pre-warmed to 37°C. 6 Cells / mL. Dilute the target plasmid (add 1 μg plasmid to 1 mL of the culture medium), dilute CHO, and then mix the two in equal volumes and gently pipette to prepare a CHO / plasmid DNA mixture. Incubate at room temperature for 1-5 min, then slowly add it to the prepared cell suspension while gently shaking. Finally, place the mixture in a cell culture shaker and culture at 37°C under CO2 conditions. 18-22 h after transfection, add ExpiCHO to the culture medium. TM Enhancer and ExpiCHO TM Feed, and place the shake flasks in a shaker at 32°C and 5% CO2 for further incubation. On day 5 post-transfection, add the same volume of ExpiCHO. TMFeed slowly while gently mixing the cell suspension. 7-15 days after transfection, centrifuge the cell culture supernatant expressing the target protein at 15000 g for 10 min. Perform affinity purification on the obtained supernatant to elute the target protein, neutralize, and then transfer the obtained protein to PBS buffer via ultrafiltration concentration tube.

[0438] 4.2 Determination of the concentration of anti-TL1A and IL23P19 bispecific antibodies The concentration of the purified bispecific antibody from Example 4.1 was determined using an ultra-micro spectrophotometer. The A280 value was divided by the theoretical extinction coefficient of the antibody and used as the antibody concentration value for subsequent studies. After passing quality inspection, the antibody was aliquoted and stored at -80℃.

[0439] 4.3 SDS-PAGE identification of anti-TL1A and IL23P19 bispecific antibodies The bispecific antibody from Example 4.1 was identified using conventional SDS-PAGE methods in the art.

[0440] Preparation of non-reducing solution: 1 µg of candidate bispecific antibody and control were added to 5×SDS loading buffer and 40 mM iodoacetamide, heated in a dry bath at 75 ℃ for 10 min, cooled to room temperature, centrifuged at 12000 rpm for 5 min, and the supernatant was collected.

[0441] Preparation of reducing solution: Add 2 µg of candidate bispecific antibody and control to 5×SDS loading buffer and 5 mMDTT, heat in a dry bath at 100 ℃ for 10 min, cool to room temperature, centrifuge at 12000 rpm for 5 min, and collect the supernatant. Add the supernatant to a Bis-tris 4-15% gradient gel and perform electrophoresis at a constant voltage of 110 V. When Coomassie Brilliant Blue migrates to the bottom of the gel, stop the run, remove the gel slide and place it in Coomassie Brilliant Blue staining solution for 1-2 h, discard the staining solution, add destaining solution, and change the destaining solution 2-3 times as needed. Destain until the gel background is transparent, and then store in deionized water. After destaining, scan with an EPSON V550 color scanner, and calculate the purity of reduced and non-reduced bands using ImageJ according to the peak area normalization method.

[0442] The results showed that the bands of the candidate bispecific antibody and the control were of the expected size on both reducing and non-reducing gels, with SDS-PAGE (%) greater than 95% and SEC-HPLC (%) greater than 98%.

[0443] Example 5: Affinity activity analysis of anti-TL1A and IL23P19 bispecific antibodies 5.1 The binding affinity of the above-mentioned bispecific antibodies to TL1A and IL23 proteins was determined by surface plasmon resonance (Biacore 100X; Cytiva). Protein A (Cytiva; 29127556) was immobilized on the sensor chip for antibody capture (experimental channel Fc2). The reference channel Fc1 did not require ligand capture. The bispecific antibody molecule was injected into Fc2 at a flow rate of 30 μL / min using running reagent (HBS-EP+buffer, pH 7.4). Human TL1A protein (ACRO, TLA-H5243) or human IL23 protein (ACRO, ILB-H52W5) was diluted to 6.25–400 nM using running reagent. The diluted human TL1A protein or IL23 was sequentially injected into the experimental and reference channels at a flow rate of 30 μL / min, allowing for binding and dissociation at the appropriate times. After each concentration analysis, the chip was regenerated for 30 s with glycine hydrochloride at pH 1.5 at a flow rate of 30 μL / min to wash away ligands and undissociated analytes. Finally, the KD value of each molecule was calculated using Biacore 100X analysis software (Biocore Insight Evaluation Software). The reference channel (Fc1) was used for background subtraction. The antibody affinity detection results of this invention are shown in Table 4 below.

[0444] Table 4-1. Affinity kinetics (KD(M)) of 1+1 configuration bispecific antibodies

[0445] The results showed that the 1+1 configuration of the bispecific antibody molecule had good affinity and did not bind to either mouse TL1A or rat TL1A; it also did not bind to mouse IL23.

[0446] Table 4-2. Affinity kinetics (KD(M)) of 2+2 configuration bispecific antibodies

[0447] The results showed that the 2+2 bispecific antibody molecule had better affinity than the 1+1 bispecific antibody.

[0448] 5.2 Detection of the blocking ability of candidate bispecific antibodies against TLIA-DR3 and TLIA-DCR3 pathways using ELISA method Coat 1 μg / ml, 100 μl / well of DCR3 (Acro, cat:TNB-H5255) and DR3 antigen (Acro, cat:H5253) with 96-well ELISA plates and incubate overnight at 4°C. The next day, wash the plates three times with 300 µL / well of PBST, blot dry, and block with PBST and 2% BSA for 2 hours. Repeat the washing steps, washing the plates three times with PBST and incubating the samples. First, dilute biotin-human TLIA / TNFSF15 protein (Acro, cat:TLA-H52Q1) with dilution buffer. Mix 100 µL of the antibody at different dilutions and 100 µL of a 2 μg / mL biotinylated Human TL1A protein (ACROBIO, TLA-H52Q1) in equal volumes. Add 100 µL of the mixture to the pre-coated 96-well ELISA plate and incubate for about 1 hour. After washing three times with PBST, the plate was incubated with SA-HRP secondary antibody (Acro, STN-NH913) for 30 min. Following incubation, the plate was washed three times with PBST and then incubated with TMB for color development. Based on the color development results, the reaction was terminated by adding 2 M HCl, and the absorbance at 450 nm was read using a microplate reader (Molecular Devices, SpecterMax 190). PRISM was then used to analyze the results. TM Analyze the data and calculate the EC50 value.

[0449] Combined with the measurement results, such as Figures 2A-2B As shown, the bispecific antibody can effectively block the binding of TLIA and DR3 receptors.

[0450] DCR3 (decoy receptor) is a soluble member of the TNF receptor family. It acts as a competitive inhibitor, binding to TLIA and preventing its interaction with the functional receptor DR3 to regulate TLIA. Through this mechanism, DCR3 can effectively inhibit the signaling pathway connected to TLIA, thereby weakening the immune response. Compared with Yangshen, the bispecific molecule in this study does not block the TLIA-DCR3 signaling pathway and is more conducive to immune regulation and tolerance.

[0451] Example 6: Competitive SPR detection of anti-TL1A and IL23P19 bispecific antibody conformations Protein A (Cytiva; 29127555) was immobilized on the sensor chip for antibody capture (experimental channel Fc2), while the reference channel Fc1 did not require ligand capture. The bispecific antibody molecule was injected into Fc2 at a flow rate of 10 μL / min using running reagent (HBS-EP+Buffer pH 7.4). For the affinity measurement experiment of competitive binding between the two antigens: first, antigen A was injected at a fixed concentration (10 nM) as the first injection; then, antigen B was injected at a concentration gradient onto the surfaces of channels 1 and 2 as the binding phase / second injection; finally, running buffer was injected as the dissociation phase. Human TL1A protein (ACRO, TLA-H5243) or human IL23 protein (ACRO, ILB-H52W5) was diluted to 6.25–200 nM using running reagent. The diluted human TL1A protein or IL23 was sequentially injected into the experimental and reference channels at a flow rate of 30 μL / min, with binding and dissociation times recorded accordingly. After each concentration analysis, the chip was regenerated for 30 seconds with glycine hydrochloric acid at pH 1.5 at a flow rate of 30 μL / min to wash away ligands and undissociated analytes. Finally, the KD value of each molecule was calculated using the Biocore T200 analysis software (Biocore Insight Evaluation Software). The reference channel (Fc1) was used for background subtraction. The antibody affinity detection results of this invention are listed in Table 5 below.

[0452] Table 5-1. Competitive SPR detection of bispecific antibodies

[0453] Table 5-2. Competitive SPR detection of bispecific antibodies - affinity data between ligands and analytes

[0454] Table 5-3. Competitive SPR detection of bispecific antibodies - Affinity data of ligands and analytes (simultaneous binding)

[0455] The results showed that the binding compounds at both ends of the bispecific antibody molecule of the present invention interfered with the binding compounds between the two target sites TL1A and IL23P19. Figures 3A-3C The competitive SPR detection results of B37-6m-Ab16 were further shown; Figure 3D , 3E The results of the competitive SPR detection of B37-5-Ab23 were further shown.

[0456] Example 7: Detection of human & monkey protein SPR with anti-TL1A and IL23P19 bispecific antibodies Protein A (Cytiva; 29127556) was immobilized on the sensor chip for antibody capture (experimental channel Fc2). The reference channel Fc1 did not require ligand capture. The bispecific antibody molecule was injected into Fc2 at a flow rate of 10 μL / min using running reagent (HBS-EP+buffer pH 7.4). Human TL1A protein (ACRO, TLA-H5243), monkey TL1A protein (ACRO, TLA-C5241), or human IL23 protein (ACRO, ILB-H52W5) were diluted to 12.5–400 nM using running reagent. Monkey IL23 protein (Kaika, IL2-CM123) was diluted to 6.25–200 nM using running reagent. The diluted human and monkey TL1A protein or IL23 were sequentially injected into the experimental and reference channels at a flow rate of 30 μL / min, with binding and dissociation times recorded. After each concentration analysis, the chip was regenerated for 30 seconds with glycine hydrochloric acid at pH 1.5 at a flow rate of 30 μL / min to wash away ligands and undissociated analytes. Finally, the KD value of each molecule was calculated using the Biocore T200 analysis software (Biocore Insight Evaluation Software). The reference channel (Fc1) was used for background subtraction. The SPR detection results of the human & monkey protein antibodies of this invention are listed in Table 5 below.

[0457] Table 6. SPR detection of human & monkey proteins with bispecific antibodies

[0458] The results showed that the specific antibody molecules of this invention had comparable affinity to human and monkey proteins at both target sites, and monkeys belong to the relevant species.

[0459] Example 8: Detection of the blocking activity of anti-TL1A and IL23P19 bispecific antibodies based on reporter gene assay. This embodiment uses a luciferase reporter gene system to detect the activity of candidate anti-TL1A and IL23 bispecific antibodies. The specific method is as follows: Prepare 96-well white-bordered transdermal cell culture plates and adjust the density of Human DR3 (TL1A receptor) (Luc) Jurkatreporter cells to 1.0E6 cells / ml. Add 50 μL / well to each well of the plate, resulting in 5E4 cells / well. Incubate at 37°C. Mix equal volumes of 40 µL of 800 nM (4X) antibody and 40 µL of 0.8 μg / ml Human TL1A Protein (Acro, TLA-H5243), and incubate at 37°C for 30 min. Then, add 50 μL of the antibody-antigen mixture to the prepared 96-well white-bordered plates containing 5E4 cells / well and incubate at 37°C for 5 h. Remove the plate from the 37℃ CO2 incubator, add 100 µl of GMOne-step luciferase reporter gene assay reagent (Jiman Biotechnology, GM-040513A), incubate at room temperature for 10 min, observe cell lysis under a microscope, and read the RLU fluorescence value using a micrometer.

[0460] Human IL23R / IL12R beta1(Luc)HEK293 reporter cells were digested with trypsin, and the cell density was adjusted to 3E4 cells / ml using assay buffer. 100 µl / well was added to each well of a 96-well plate and incubated overnight at 37°C. The next day, the antibody and antigen to be tested were diluted. 60 µl of serially diluted antibody and 60 µl of 0.2 µg / ml IL23 antigen were added to equal volumes and incubated at 37°C for 30 min. The overnight cultured 96-well plate was removed, the supernatant was gently aspirated, and 100 µl / well of the above-mentioned antigen-antibody mixture was added to each well of the plate after discarding the supernatant. The plate was incubated at 37°C for 5 h. The plate was removed from the 37°C CO2 incubator, and 100 µl of GMOne-step luciferase reporter gene assay reagent was added. The plate was incubated at room temperature for 10 min, and cell lysis was observed under a microscope. RLU fluorescence values ​​were read. Analyze the data using PRISM™ and calculate the EC50 value.

[0461] Figures 4A-4E The results of reporter gene blocking activity were shown, indicating that the bispecific antibody molecule TL1A and IL23 of the present invention have comparable activities at both ends to the positive label, and have a complete blocking effect.

[0462] Example 9: Blocking activity of primary PBMCs and mouse spleen cells 9.1 Candidate antibody inhibits TLIA-induced IFNγ secretion Human PBMC cells (Sino Biologics, cat: XFB-HP025B) in liquid nitrogen were rapidly thawed in a water bath and then transferred to 50 ml centrifuge tubes containing RPM11 640 medium (containing 20 U / ml DNase 1). The cells were centrifuged at 200 g for 15 min, and the supernatant was discarded. Cells were resuspended in 4 ml of RPM11 medium for counting. PBMCs resuspended in medium at a cell density of 1E6 cells / ml were added to 100 μl / well of a 96-well plate and incubated overnight at 37°C. Three antigens—250 μg / ml IL12 (Sino Biologics, CT050-H28HE), 150 μg / ml IL18 (Sino Biologics, 10119-HNCE), and 600 μg / ml TLIA (Acro, TLA-H5243)—were mixed, and the antibody to be tested was diluted using the IL12, IL18, and TLIA protein mixture as a diluent. Add the antibody serially diluted with the antigen mixture, mix well, and incubate at 37°C for 30 min. Add 100 μL / well to a 96-well plate containing 100 μL of pre-coated PBMC cells, and add control wells (wells with only cytokine stimulation and wells with only culture medium). Incubate the plate at 37°C for 3 days. After 72 h, remove the 96-well U-bottom sample reaction plate from the incubator, centrifuge at 2000 rpm for 15-20 min, collect the supernatant, and dilute 50 μL of the supernatant for detection. Analyze using the Human IFN-R procoated ELISA kit (Acro, human IFN-R precoated ELISA kit, cat: CRS-A017), and read the OD450 value for analysis.

[0463] 9.2 Candidate antibody inhibits IL-17 secretion induced by IL-23 in mouse spleen cells This embodiment aims to determine whether the bispecific antibody molecule of the present invention can reduce the production of the downstream signal IL17 induced by IL-23. In vitro, serially diluted Yangshen antibody, the bispecific antibody of the present invention, and IL23 protein were premixed and added to mouse spleen cells for observation. The specific method is as follows: Mouse spleen lymphocytes were isolated using standard methods in the art. The mice (Balb / c) were euthanized by cervical dislocation, disinfected, and placed on a mouse dissection board in a laminar flow hood in the left lateral position, with the limbs fixed with needles. The spleen was aseptically removed from the abdominal cavity and washed with PBS to remove surrounding connective tissue. A cell strainer was placed in another culture dish containing PBS, and the spleen was placed within the strainer. The tissue was crushed using the end of a syringe to gradually release the cells from the membrane, creating a spleen cell suspension. The suspension containing mouse spleen lymphocytes was collected, centrifuged at 1000 rpm for 10 min, the supernatant was discarded, and the cells were resuspended in 5 ml of ACK lysis buffer (Sigma). After lysis for 3 minutes, the cells were centrifuged at 1000 rpm for 10 min. The cells were washed once with 30 ml of PBS, centrifuged again to discard the supernatant, and resuspended in 5 ml of complete culture medium (RPMI 1640 + 10% FBS). The cell suspension was then obtained and the cells were counted. Take 10 μL of the spleen cell suspension obtained in the above operation, count the cells, and dilute the cell density to 4E6 cells / ml with complete culture medium. Plate the cells into 96-well plates at 100 μL / well, with 4E5 cells per well, and incubate at 37°C. Dilute the IL23 protein concentration to 120 ng / ml, and then mix equal volumes of serially diluted antibody and 120 ng / ml IL23 antigen. Incubate at 37°C for 30 min. Add the mixture to control wells, wells containing IL23 mixed with culture medium, and wells containing IL23 mixed with spleen cells. After 30 min, add 100 μL of the mixture to a 96-well plate already plated with mouse spleen lymphocytes, mix well, and incubate at 37°C for 72 h (3 days). Collect the culture supernatant and detect the secretion of IL17 using a mouse IL17 kit (see Dakota, product number: 1211702 for instructions).

[0464] Figures 5A-5F The bispecific antibody molecule was demonstrated to have blocking activity in primary PBMCs and mouse spleen cells. The results indicate that the bispecific antibody molecule of this invention has the ability to block the release levels of IFN-γ and IL-17; the bispecific antibody molecule of this invention has TL1A-terminal PBMC blocking activity; and it has IL23-terminal blocking activity in mouse spleen cells, with blocking ability comparable to that of a positive label.

[0465] Example 10: Pharmacodynamic experiment of the test substance in a TNBS-induced enteritis model in B-hTL1A / hIL23A / hIL12B mice. This embodiment uses humanized animals targeting TL1A / IL23 / IL12B, which is suitable for the pharmacological and safety evaluation of antibody drugs targeting TL1A, IL23, etc. in autoimmune diseases such as inflammatory bowel disease, psoriasis, and arthritis, and evaluates the bispecific antibody molecule of the present invention.

[0466] 10.1 Validation of the efficacy of B37-6m-Ab25: hTL1A / hIL23A / hIL12B mice (Biocytogen, female, 8-10 weeks old) were randomly divided into 9 groups according to body weight after acclimatization: Sham group, model group, low, medium, and high dose groups of B37-6m-Ab25 (7, 14, and 35 mg / kg), low and high dose groups of PRA023 (10 and 25 mg / kg), and low and high dose groups of Risankizumab (10 and 25 mg / kg). The mice were fasted on Day 0 before modeling: the Sham group received 100 μL of ddH2O rectally; the other 8 groups received 100 μL of 1.5% TNBS solution rectally. The test substance was administered intravenously once on Day 1 and Day 2, with the experimental period lasting 9 days (Day 1-Day 7), and Day 7 being the experimental endpoint. After modeling, the body weight of the experimental animals was recorded daily, and the Disease Activity Index (DAI) score was calculated to evaluate the morbidity and efficacy of the test drug in each group. At the endpoint, the mice were euthanized, and the colon (from anus to cecum) was collected, its length was measured, and its weight was weighed.

[0467] Figures 6A-6D This study demonstrates the efficacy of the bispecific antibody molecule of the present invention in a TNBS-induced enteritis model in B-hTL1A / hIL23A / hIL12B mice. Results showed that B37-6m-Ab16 significantly improved body weight and DAI scores in enteritis mice in a dose-dependent manner, and significantly improved colon length, weight, and morphology in diseased mice, restoring them to near-normal levels, and significantly ameliorated disease progression. B37-6m-Ab25 improved DAI scores and body weight loss in a TNBS-induced CD model in a dose-dependent manner; higher doses resulted in earlier onset of action and stronger efficacy. At the same doses of 14 and 35 mg / kg, B37-6m-Ab25 was slightly better than the single-target PRA023 in improving DAI scores, and significantly better than Risankizumab. All treatment groups showed the effect of delaying the progression of CD model and reducing the mortality rate of the model; B37-6m-Ab25 dose-dependently prolonged the colon length of CD mouse model and reduced colon weight and colon density; 14 and 35 mg / kg B37-6m-Ab25 improved colon length, colon weight and colon density, which was superior to positive markers PRA023 and Risankizumab.

[0468] 10.2 Validation of the efficacy of B37-6m-Ab16: Using the same experimental model and methods as in Example 10.1, the efficacy of B37-6m-Ab16 was validated at doses of 8.85 mpk and 17.7 mpk. The results showed that the bispecific antibody molecule B37-6m-Ab16 of this invention significantly improved the progression of enteritis in mice, dose-dependently improving body weight and DAI scores, and significantly improving colon length, weight, and morphology in diseased mice, restoring them to near-normal levels.

[0469] Those skilled in the art will recognize that many modifications and variations can be made to the invention without departing from its spirit and scope. The specific embodiments described herein are provided by way of example only and are not intended to limit the scope in any way. The true scope and spirit of the invention are shown in the appended claims, and the description and embodiments are merely exemplary.

[0470] Partial sequence information .

Claims

1. A bispecific antibody comprising a first antigen-binding moiety binding to TL1A and a second antigen-binding moiety binding to IL23P19, wherein the first antigen-binding moiety binding to TL1A comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and the light chain variable region comprising LCDR1, LCDR2, and LCDR3, wherein the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are selected from: (1) HCDR1, comprising the amino acid sequence of SEQ ID NO: 1; HCDR2, comprising the amino acid sequence of SEQ ID NO: 2; HCDR3, comprising the amino acid sequence of SEQ ID NO: 3; LCDR1, comprising the amino acid sequence of SEQ ID NO: 4; LCDR2, comprising the amino acid sequence of SEQ ID NO: 5; and LCDR3, comprising the amino acid sequence of SEQ ID NO: 6; or (2) HCDR1, comprising the amino acid sequence of SEQ ID NO: 7; HCDR2, comprising the amino acid sequence of SEQ ID NO: 8; HCDR3, comprising the amino acid sequence of SEQ ID NO: 9; LCDR1, comprising the amino acid sequence of SEQ ID NO: 10; LCDR2, comprising the amino acid sequence of SEQ ID NO: 11; and LCDR3, comprising the amino acid sequence of SEQ ID NO: 12; or 3) HCDR1, comprising the amino acid sequence of SEQ ID NO: 7; HCDR2, comprising the amino acid sequence of SEQ ID NO: 8; HCDR3, comprising the amino acid sequence of SEQ ID NO: 9; LCDR1, comprising the amino acid sequence of SEQ ID NO: 97; LCDR2, comprising the amino acid sequence of SEQ ID NO: 11; and LCDR3, comprising the amino acid sequence of SEQ ID NO: 12; or (4) HCDR1, comprising the amino acid sequence of SEQ ID NO: 7; HCDR2, comprising the amino acid sequence of SEQ ID NO: 98; HCDR3, comprising the amino acid sequence of SEQ ID NO: 9; LCDR1, comprising the amino acid sequence of SEQ ID NO: 10; LCDR2, comprising the amino acid sequence of SEQ ID NO: 11; and LCDR3, comprising the amino acid sequence of SEQ ID NO: 12; or (5) HCDR1, which contains the amino acid sequence of SEQ ID NO: 7; HCDR2, which contains the amino acid sequence of SEQ ID NO: 98; HCDR3, which contains the amino acid sequence of SEQ ID NO: 9; LCDR1, which contains the amino acid sequence of SEQ ID NO: 97; LCDR2, which contains the amino acid sequence of SEQ ID NO: 11; and LCDR3, which contains the amino acid sequence of SEQ ID NO:

12.

2. The bispecific antibody of claim 1, wherein the heavy chain variable region and the light chain variable region of the first antigen-binding portion of TL1A are selected from: (1) the heavy chain variable region, which comprises the amino acid sequence of SEQ ID NO: 13; (1) Light chain variable region containing the amino acid sequence of SEQ ID NO: 14; or, (2) Heavy chain variable region containing the amino acid sequence of SEQ ID NO: 15; (3) Light chain variable region containing the amino acid sequence of SEQ ID NO: 16; or, (4) Heavy chain variable region containing the amino acid sequence of SEQ ID NO: 29; light chain variable region containing the amino acid sequence of SEQ ID NO: 30; (5) Heavy chain variable region containing the amino acid sequence of SEQ ID NO: 31; light chain variable region containing the amino acid sequence of SEQ ID NO: 32; (6) Heavy chain variable region containing the amino acid sequence of SEQ ID NO: 82; light chain variable region containing the amino acid sequence of SEQ ID NO:

83.

3. The bispecific antibody of claim 1 or 2, wherein the second antigen-binding portion binding IL23P19 comprises a heavy chain variable region, the heavy chain variable region comprising: (1) the amino acid sequence of SEQ ID NO: 23; or, (2) the amino acid sequence of SEQ ID NO: 24; or, (3) the amino acid sequence of SEQ ID NO:

28.

4. The bispecific antibody as described in claim 1 or 2, wherein the second antigen-binding moiety binding to IL23P19 comprises a heavy chain variable region and a light chain variable region, wherein, The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 28; the light chain variable region contains the amino acid sequence of SEQ ID NO:

78.

5. The bispecific antibody according to any one of claims 1 to 4, comprising a heavy chain constant region CH1 of an immunoglobulin; preferably, the heavy chain constant region CH1 is a heavy chain constant region CH1 of human IgG1 or human IgG4; more preferably, the heavy chain constant region comprises an amino acid sequence such as SEQ ID NO:

37.

6. The bispecific antibody according to any one of claims 1 to 5, further comprising a heavy chain hinge region of an immunoglobulin, wherein the heavy chain hinge region is a heavy chain hinge region of human IgG1 or human IgG4; preferably, the heavy chain hinge region comprises the amino acid sequence of SEQ ID NO:39 or SEQ ID NO:

40.

7. The bispecific antibody according to any one of claims 1 to 6, further comprising an Fc fragment of an immunoglobulin, wherein the Fc fragment is an amino acid sequence such as SEQ ID NO:38, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 or SEQ ID NO:

46.

8. The bispecific antibody according to any one of claims 1 to 7, further comprising a light chain constant region (CL) of an immunoglobulin, said light chain constant region being a human κ light chain constant region or a human λ light chain constant region; preferably, said light chain constant region comprising an amino acid sequence such as SEQ ID NO:

50.

9. The bispecific antibody according to any one of claims 1 to 8, further comprising one or more adapters, said adapters being GS adapters; preferably, said adapters comprise an amino acid sequence such as SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:84 or SEQ ID NO:

85.

10. The bispecific antibody according to any one of claims 1 to 9, comprising a first polypeptide chain and a second polypeptide chain; wherein, The first polypeptide chain comprises the heavy chain variable region of the first antigen-binding moiety of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as described in claim 5, the heavy chain hinge region of the immunoglobulin as described in claim 6, the Fc fragment of the immunoglobulin as described in claim 7, the linker as defined in claim 9, and the light chain variable region and / or heavy chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4; and The second polypeptide chain comprises the light chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2 and the light chain constant region of the immunoglobulin as described in claim 8.

11. The bispecific antibody according to any one of claims 1 to 9, comprising a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain; wherein, The first polypeptide chain comprises the heavy chain variable region of the second antigen-binding portion of IL23P19 as defined in claims 3-4, the linker as defined in claim 9, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7. The second polypeptide chain comprises the heavy chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7. The third polypeptide chain comprises the light chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2 and the light chain constant region of the immunoglobulin as defined in claim 8.

12. The bispecific antibody according to any one of claims 1 to 9, comprising a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain; wherein, The first polypeptide chain includes the heavy chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, the Fc fragment of the immunoglobulin as defined in claim 7, the linker as defined in claim 9, and the heavy chain variable region of the second antigen-binding portion of IL23P19 as described in claims 3-4. The second polypeptide chain comprises the heavy chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7. The third polypeptide chain comprises the light chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2 and the light chain constant region of the immunoglobulin as defined in claim 8.

13. The bispecific antibody of claim 10, wherein, The first polypeptide chain, from the N-terminus to the C-terminus, comprises the heavy chain variable region of the first antigen-binding moiety of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, the Fc fragment of the immunoglobulin as defined in claim 7, the linker as defined in claim 9, the heavy chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4, the linker as defined in claim 9, and the heavy chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4; or The first polypeptide chain, from the N-terminus to the C-terminus, comprises the heavy chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4, the linker as defined in claim 9, the heavy chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4, the linker as defined in claim 9, the heavy chain variable region of the first antigen-binding moiety of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7; or The first polypeptide chain, from its N-terminus to its C-terminus, comprises the heavy chain variable region of the first antigen-binding moiety of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, the Fc fragment of the immunoglobulin as defined in claim 7, the linker as defined in claim 9, the heavy chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4, the linker as defined in claim 9, and the light chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4; and, The second polypeptide chain includes, from the N-terminus to the C-terminus, the light chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2 and the light chain constant region of the immunoglobulin as defined in claim 8.

14. The bispecific antibody as described in claim 11, wherein, The first polypeptide chain comprises, from the N-terminus to the C-terminus, the heavy chain variable region of the second antigen-binding portion of IL23P19 as described in claims 3-4, the linker as defined in claim 9, the heavy chain variable region of the second antigen-binding portion of IL23P19 as described in claims 3-4, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7. The second polypeptide chain, from its N-terminus to its C-terminus, comprises the heavy chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7; or, the second polypeptide chain, from its N-terminus to its C-terminus, comprises the heavy chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the linker as defined in claim 9, the heavy chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7. as well as The third polypeptide chain, from the N-terminus to the C-terminus, comprises the light chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2 and the light chain constant region of the immunoglobulin as defined in claim 8; or, the third polypeptide chain, from the N-terminus to the C-terminus, comprises the light chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the linker as defined in claim 9, the light chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, and the light chain constant region of the immunoglobulin as defined in claim 8.

15. The bispecific antibody as described in claim 12, wherein, The first polypeptide chain, from its N-terminus to its C-terminus, comprises the heavy chain variable region of the first antigen-binding moiety of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, the Fc fragment of the immunoglobulin as defined in claim 7, the linker as defined in claim 9, the heavy chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4, the linker as defined in claim 9, and the heavy chain variable region of the second antigen-binding moiety of IL23P19 as described in claims 3-4; or, The first polypeptide chain, from the N-terminus to the C-terminus, comprises the heavy chain variable region of the second antigen-binding portion of IL23P19 as described in claims 3-4, the linker as defined in claim 9, the heavy chain variable region of the second antigen-binding portion of IL23P19 as described in claims 3-4, the linker as defined in claim 9, the heavy chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7. The second polypeptide chain comprises, from the N-terminus to the C-terminus, the heavy chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2, the heavy chain constant region CH1 of the immunoglobulin as defined in claim 5, the heavy chain hinge region of the immunoglobulin as defined in claim 6, and the Fc fragment of the immunoglobulin as defined in claim 7. as well as The third polypeptide chain includes, from the N-terminus to the C-terminus, the light chain variable region of the first antigen-binding portion of TL1A as described in claims 1-2 and the light chain constant region of the immunoglobulin as defined in claim 8.

16. The bispecific antibody of claim 11, wherein, The first polypeptide chain comprises 1) an amino acid sequence such as SEQ ID NO:51, 56, 60, 61, 62, 63, 64, 65, 66, 67, 74, 75, 76, 77; or 2) an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:51, 56, 60, 61, 62, 63, 64, 65, 66, 67, 74, 75, 76, 77; and / or The second polypeptide chain comprises 1) an amino acid sequence such as SEQ ID NO:34, 52, 53, 54, 57, 58, 59, 68, 70, 72, 73; or 2) an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:34, 52, 53, 54, 57, 58, 59, 68, 70, 72, 73; and / or The third polypeptide chain comprises 1) an amino acid sequence such as SEQ ID NO:34, 36, 55, 69, 71; or 2) an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:34, 36, 55, 69, 71.

17. The bispecific antibody according to any one of claims 1-16, comprising a polypeptide chain selected from any one of the following (1) to (24): (1) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:51; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:52; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

34. (2) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:51; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:53; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

36. (3) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:51; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:53; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

34. (4) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:51; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:54; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

55. (5) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:56; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:57; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

36. (6) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:56; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:57; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

34. (7) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:56; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:58; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

55. (8) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:56; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:59; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

34. (9) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:60; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:34; (10) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:61; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:34; (11) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:62; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:34; (12) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:63; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:34; (13) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:64; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:59; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

34. (14) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:66; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:57; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

34. (15) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:65; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:59; and a third polypeptide chain comprising the amino acid sequence of SEQ ID NO:

34. (16) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:67; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:57; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

34. (17) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:56; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:68; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

69. (18) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:56; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:70; and a third polypeptide chain comprising the amino acid sequence of SEQ ID NO:

71. (19) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:56; a second polypeptide chain containing the amino acid sequence of SEQ ID NO:72; and a third polypeptide chain containing the amino acid sequence of SEQ ID NO:

69. (20) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:56; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:73; and a third polypeptide chain comprising the amino acid sequence of SEQ ID NO:

71. (21) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:74; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:34; (22) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:75; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:34; (23) A first polypeptide chain comprising the amino acid sequence of SEQ ID NO:76; a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:34; (24) A first polypeptide chain containing the amino acid sequence of SEQ ID NO:77; and a second polypeptide chain containing the amino acid sequence of SEQ ID NO:

34.

18. A pharmaceutical composition comprising the bispecific antibody as described in any one of claims 1 to 17 and a pharmaceutically acceptable carrier thereof.

19. Use of the bispecific antibody as described in any one of claims 1 to 17 or the pharmaceutical composition as described in claim 18 in the preparation of a medicament for treating autoimmune diseases, inflammatory or allergic diseases, organ transplantation and allogeneic immune diseases, and immunodeficiency diseases.

20. A polynucleotide encoding the bispecific antibody according to any one of claims 1 to 17.

21. An expression vector comprising the polynucleotide of claim 20.

22. A host cell comprising the polynucleotide of claim 20 or the expression vector of claim 21.

23. A method for producing a bispecific antibody as described in any one of claims 1 to 17, the method comprising: a) Culturing the host cell of claim 22 under suitable conditions to express the bispecific antibody of any one of claims 1 to 17; and b) Isolating the bispecific antibody from the host cell or its culture.

24. Use of the bispecific antibody as described in any one of claims 1 to 17 and the pharmaceutical composition as described in claim 18 in the treatment and / or prevention of immune diseases.

Citation Information

Patent Citations

  • Compositions that mediate killing of HIV-infected cells

    WO1993008829A1

  • Human Anti-il-23 antibodies, compositions, methods and uses

    WO2007076524A2

  • Amino acid sequences directed against heterodimeric cytokines and / or their receptors and polypeptides comprising the same

    WO2009068627A2

  • Anti-il-23p19 antibodies

    WO2013165791A1

  • Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof

    WO2015073580A1